Peter MacCallum Cancer Centre/Royal Melbourne Hospital
Walter and Eliza Hall Institute of Medical Research
Melbourne University

***Curriculum vitae* for Professor Andrew Wei**

Date of Preparation 16th July 2022

A. GENERAL INFORMATION

1. Name: **Andrew Wei, MBBS, PhD**

2. Office Address: Victorian Comprehensive Cancer Centre
Level 9, 305 Grattan Street,
Melbourne, 3002

B. BIOSKETCH

As a clinical haematologist [MBBS 1993, FRACP 2002 (Haematology)], haematopathologist [FRCPA 2002] and current Medical Research Future Fund (MRFF) clinical fellow (2018-2022), my career focus has been to conduct and develop clinical trials for patients with acute myeloid leukaemia. These activities are supported by a research lab that utilizes patient-derived samples to interrogate mechanisms of resistance to novel therapies and to validate new drug combinations for clinical development. My research doctorate at the Walter and Eliza Hall Institute of Medical Research [PhD 2005 (University of Melbourne)] produced two seminal papers that defined functional relationships between BCL-2 family members (*Molecular Cell* 2005; cited 1,424 times [*PMID 10456139*]) and the importance of targeting MCL1 to enhance activity of the BH3-mimetic ABT-737 (*Cancer Cell* 2006; cited 990 times [*PMID 10456147*]). I joined the Alfred Hospital in 2008 to develop the AML program there. Since then, I have conducted over 50 clinical trials, which include studies leading to FDA approval of four drugs; Venetoclax (*JCO* 2019; lead author and *NEJM* 2020; cited 498 times), CC-486 (*NEJM* 2020; lead author), Midostaurin (*NEJM* 2017; sited 748 times) and Blinatumomab (*NEJM* 2017; cited 663 times). I have a total of 138 publications, resulting in 11,314 citations (Scopus) and an H-index of 38. I currently hold an active MRFF clinical fellowship and have led successful NHMRC, VCA and MRFF grants as CIA. I also led an ACRF grant to establish the Blood Cancer Therapeutics Centre at the Alfred in 2017. In total, I have been awarded a total of >$17M in peer-reivewed funding as CIA. I hold AML leadership positions, including chair of the national AML trials program in Australia for the Australasian Leukaemia and Lymphoma Group (ALLG), where I have led development of the National Blood Cancer Registry in AML (AML M18) and several national AML clinical trials (AML M15, M16, M17, M21, M22, M24 and M25). I am also a member of the European LeukemiaNet international AML guidelines committee (*Blood* 2017; cited 1,818 times) and global AML advisory boards for Novartis, Amgen, Astra Zeneca, Celgene, Servier, Bayer, Agios and Genentech. I am a member of the federal Independent Hospital Pricing Authority Clinical Advisory Committee, the executive committee of the Cancer Council Victoria Clinical Network and the editorial boards for the leading journals *Blood* and *Journal of Clinical Oncology*. I have also mentored several successful clinical fellows, including Shaun Fleming, Ing-Soo Tiong and Chong Chyn Chua as well as post-docotoral fellows Fiona Brown to receive an NHMRC investigator grant and Donia Moujalled to receive a VCA mid-career fellowship.

C. ACADEMIC BACKGROUND

1987-1993 MBBS University of Melbourne

2002-2005	PhD	Walter and Eliza Hall Institute, University of Melbourne
2002	FRACP	Royal Australasian College of Physicians
2002	FRCPA	Royal College of Pathologists Australasia
2019		Certification for Genetic/Genomic Testing for Non-Genetic Pathologists- Haematology- RCPA

D. PROFESSIONAL POSITIONS AND EMPLOYMENT

Current Positions

2022-Present	Clinical Haematologist	Peter MacCallum Cancer Centre/Royal Melbourne Hospital
2022-Present	Laboratory Head	Division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute of Medical Research
2008-1/2022	Clinical Haematologist	Alfred Hospital
2016-Present	Head Human Molecular Pathology	Alfred Hospital
2019-Present	Ambassador|Australia for the Society of Hematologic Oncology (SOHO)	
2020-Present	Adjunct Professor	Monash University
2021-Present	Honorary Professorial Fellow	Melbourne University
2021-Present	Laboratory Head, Blood Cells and Blood Cancer	Walter and Eliza Hall Institute

Previous appointments

2002-2005	PhD	Walter and Eliza Hall Institute
2005-2006	Staff haematologist	Box Hill Hospital
2005-2006	Staff haematologist	Monash Medical Centre
2007-2008	Staff haematologist	St Vincent's Hospital
2008-2013	Adjunct senior lecturer	Monash University
2013-2020	Adjunct Associate Professor	Monash University

E. AWARDS AND FELLOWSHIPS

2002 Leukaemia Foundation Max Whiteside Clinical Fellowship: $70,000
2003 Albert Baikie Award, Haematology Society of Australia, Christchurch
2003 Young Investigator Award
2003 RACP Annual Scientific Meeting, Hobart
2003 Leukaemia Foundation Max Whiteside Clinical Fellowship: $80,000
2004 New Investigator Award, RACP Annual Scientific Meeting, Canberra
2011 Victorian Cancer Agency Clinical Fellowship: $400,000
2014 Monash Partners Academic Health Science Centre Research Fellowship: $400,000
2018 Clinical Practitioner Fellowship- Medical Research Future Fund: $407,000
2021 Alfred Research Alliance Prize for Clinical/Public Health Research

F. ADVISORY BOARDS

2013 Celgene- Global AML advisory board, Stockholm
2013 Novartis APECHO- Chair, Asia-Pacific advisory board, Hong Kong
2013 Novartis Lead Summit XI- Haematological diseases advisory board, Hungary
2013 Abbvie/Genentech-Global AML Advisory Board for ABT-199, New Orleans
2013 Amgen- Chair, Blinatumomab Advisory Board, Melbourne
2014 Novartis Lead Summit XII- Chair, Advisory Board: AML and MF, Montreal
2014 Servier- Global AML Advisory Board, Paris

2014 American Society of Hematology- ASH Abstract reviewer
2014 Amgen- Global Blinatumomab Advisory Board, San Francisco
2014 Bayer- Global AML Advisory Board, San Francisco
2014 Astra Zeneca- Global AML Advisory Board, San Francisco
2014 Agios- Global AML Advisory Board, San Francisco
2015 Celgene- Global AML Advisory Board, Barcelona
2015 American Society of Hematology- ASH Abstract reviewer chair for AML Novel Therapies, excluding Transplantation
2015 Novartis APECHO- Asia-Pacific advisory board, Taiwan
2015 Roche- Global AML Advisory Committee, Orlando
2016 Servier- Global AML Advisory Board, Paris
2016 Abbvie- Venetoclax Global AML Advisory Committee, San Diego
2016 Novartis- Midostaurin Global AML Advisory Committee, San Diego
2017 Celgene- CC-486 Global AML Advisory Committee, New York
2018 Abbvie- Venetoclax Global AML Advisory Committee, San Diego
2018 Amgen- AML Global Advisory Committee, San Diego

G. PEER REVIEW RESPONSIBILITIES

Editorial Boards
Editorial Board, **Blood** (2017-)
Editorial Board, **Journal of Clinical Oncology** (Jan 2020- Dec 2022)

Reviewer:
American Journal of Medical Sciences
Blood
British Journal of Hematology
Clinical Cancer Research
Experimental Hematology
Hematologica
Internal Medicine Journal
Lancet Oncology
Leukemia
Leukemia and Lymphoma
Leukemia Research
Molecular Cancer Therapeutics
Oncogene
Oncotarget
Scientific reports
Abstract reviewer, American Society of Hematology meeting 2014, 2015: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
Coordinating Abstract reviewer, American Society of Hematology meeting 2015: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
Abstract reviewer, Hematology Society Australasia Annual Meetings, 2011, 2012, 2013
Abstract reviewer, New Directions in Leukaemia Research Meeting, 2016

H. PROFESSIONAL MEMBERSHIPS

American Society of Hematology
Royal Australasian College of Physicians
Royal College of Pathologists of Australasia
American Society of Haematology
Haematology Society of Australia and New Zealand
Australasian Lymphoma and Leukemia Group
European Haematology Association

I. COMMITTEES

2005-Present	Scientific Advsory Committee, Australasian Leukaemia and Lymphoma Group
2006	Australian Drug Evaluation Committee
2008-Present	Executive SAC, Australasian Leukaemia and Lymphoma Group
2014-Present	Cancer Council of Victoria Clinical Network Executive Committee
2014-Present	New Directions in Leukaemia Research organizing committee
2014-Present	ASH abstract reviewer committee
2015-Present	Monash Partners Comprehensive Cancer Centre Executive Committee
2015-Present	Member of European LeukemiaNet AML guidelines panel
2015-Present	Committee and panel member, Global AML Portal
2015-2016	Cancer Council Guidelines: Optimal cancer care pathway for people with acute myeloid leukaemia
2016-Present	Independent Hospital Pricing Authority Clinical Advisory Committee (National Health Reform Act 2011)
2017-Present	Victorian Cancer Registry Steering Committee
2019-Present	Scientivic Committee – International Workshop in Acute Leukemia
2020-Present	Scientivic Committee - Acute Leukemias XVIII, Munich

J. RESEARCH SUPPORT (TOTAL $12.3M)

NHMRC CLINICAL TRIALS AND COHORT STUDIES APP2006403 2022-2025
INTERCEPT (Investigating Novel Therapy to target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): a multi-arm, precision-based, recursive, platform trial
Role: CIA, $5,789,515.10

MEDICAL RESEARCH FUTURE FUND APP1169950 2019-2023
Research Grant
Novel Venetoclax Combinations to Improve Outcomes in Unfit Older Patients with Acute Myeloid Leukaemia
Role: CIA, $1,380,297.60

CANCER AUSTRALIA 2019-2022
Integrated Management of Post Remission Leukaemia to Optimise Longevity and Enhance Quality of Life
Role: CIA, $120,000

NHMRC APP1162809 2019-2022
Transforming the treatment landscape in elderly Acute Myeloid Leukaemia
Role: CIA, $1,071,166

MEDICAL RESEARCH FUTURE FUND APP1141460 2018-2022

PRACTITIONER FELLOWSHIP
Translational Research Program to Advance Clinical Outcomes in Acute Myeloid Leukaemia
Role: CIA, $412,419

PAST

NHMRC APP1145728 2018-2020
Examining the contribution of mutant DNMT3a in the development and sustained growth of Acute Myeloid Leukaemia
Role: CIC, $820,880.20

MEDICAL RESEARCH FUTURE FUND APP1152313 2018-2020
Research Grant
A registry-linked national platform trial to improve precision-based outcomes using novel therapies in acute myeloid leukaemia (AML)
Role: CIA, $1,507,785

VICTORIAN CANCER AGENCY 2017-2019
The International AML Platform Consortium
Role: CIA, $1,500,000

AUSTRALIAN CANCER RESEARCH FOUNDATION 2017-2019
The ACRF Blood Cancer Therapeutics Centre
Role: CIA, $1,200,000

NHMRC APP1126843 2017-2019
Toward effective targeted therapies for Acute Myeloid Leukaemia (AML)
Role: CIA, $551,344.60

NHMRC APP1081376 2015-2018
Targeting IAPs in Leukaemias using the Smac-mimetic drug Birinapant
Role: CID, $932,512

NHMRC APP1086662 2015-2018
Eradicating leukaemic stem cells by targeting the arginine methyltransferase PRMT5
Role: CID, $742,353

NHMRC EQUIPMENT GRANT ID9000389 2016
BD LSR Fortess X20 Flow cytometry system
Role CIK, $90,000

VCA TRANSLATIONAL RESARCH GRANT 2014-2016
BH3-mimetics in rational combination therapies to overcome treatment-resistant cancers
Role: CIB, $2,480,792

MONASH PARTNERS CLINICAL RESEARCH FELLOWSHIP 2014-2016
BH3-mimetics in rational combination therapies to overcome treatment-resistant cancers
Role: CIA, $400,000

NHMRC APP1066711 2014-2016
Targeting the apoptosis machinery in cancer
Role: CIB, $527,948
NHMRC APP1048312 2013-2017

A randomised study to optimise clinical outcomes in patients with FLT3 mutant AML
Role: CIA, $1,111,891

LEUKAEMIA FOUNDATION GRANT IN AID 2013-2014
Targeting the pro-survival machinery in acute myeloid leukaemia for therapeutic benefit
Role: CIA, $100,000

NHMRC APP1024342 2012-2014
GADD45A promoter methylation and poor prognosis in AML: mechanism and clinical significance
Role: CIB, $682,350

NHMRC APP1033248 2012-2014
Dual inhibition of independent cell survival pathways as a new approach for targeting leukemic stem cells
Role: CIB, $543,675

LEUKAEMIA FOUNDATION CLINICAL TRIAL GRANT 2011-2013
A phase 2 randomized study investigating the FLT3 inhibitor Sorafenib in sequence after intensive chemotherapy for untreated adult AML harboring FLT3 mutations
Role: CIA, $600,000

LEUKAEMIA FOUNDATION GRANT IN AID 2011-2012
Inositol phosphatase regulation of PI3-kinase activity: defining their role as collaborators in leukaemogenesis
Role: CIA, $100,000

VCA CLINCAL FELLOWSHIP 2011-2012
Targeting PI3K in AML
Role: CIA, $400,000

LEUKAEMIA FOUNDATION GRANT IN AID 2010-2011
Targeting PI3K and the bone marrow microenvironment for therapeutic benefit in leukaemia
Role: CIA, $100,000

PFIZER CANCER RESEARCH GRANT 2009-2010
Targeting the bone marrow microenvironment for therapeutic benefit in leukemia
Role: CIA, $50,000

VCA SEED GRANT 2009-2010
Epigenetics and Cancer Therapy
Role: CIA, $50,000

MAX WHITESIDE CLINICAL FELLOWSHIP 2003-2004
Apoptosis in haematological malignancies
Role: CIA, $160,000

MAX WHITESIDE CLINICAL FELLOWSHIP 2002-2003
Apoptosis in haematological malignancies
Role: CIA, $70,000

INVESTIGATOR- LED CLINICAL TRIAL FUNDING (TOTAL $3.71M)

2017 $800,000 CIA- Maintenance platform study- Venetoclax domain

2016 $240,000 CIA- Mapping the fate of IDH mutant AML in Australia

2016 $94,000 CIA- Chemotherapy and Venetoclax in Elderly AML Trial

2013 $469,500 CIA- A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacytidine in patients with FLT3-ITD AML failing chemotherapy

2011 $857,500 CIA- A strategy of high-dose lenalidomide in combination with epigenetic therapies for relapsed and refractory MDS/AML

2010 $450,000 CIA- A phase Ib/II study of Lenalidomide maintenance in AML

2009 $377,000 CIA- Phase Ib/II Clinical Evaluation of the Safety of Combining the mTOR inhibitor Everolimus with 5-azacytidine in Elderly Patients with AML

2009 $177,000 CIA- A Phase Ib/II Clinical Evaluation of the Safety of Combining the Lenalidomide with 5-azacytidine as maintenance therapy in AML

2008 $242,000 CIA- A Phase 1 Dose Finding Study of RAD001 in Elderly Patients with Acute Myeloid Leukemia (AML) Unfit for Intensive Induction Chemotherapy

OTHER GRANTS ($1.07M)

2016 Alfred foundation grant- Next Seq $317,000
2014 Gel count $50,000
2013 Alfred grant for a liquid handling robot $56,000
2013 Alfred Foundation equipment grant: $322,000 for purchase of a Sequenom MassArray
2011 Alfred Foundation grant: $188,000 CIA- The Alfred Biomarker Facility
2011 Alfred Foundation grant: $66,250 CIA- Development of dual kinase inhibitors for leukaemia
2010 Alfred Hospital Equipment Grant $64,893 CIA
2006 European Commission Marie Curie Actions Scholarship to present at the European society of Haematolgy/American Association of Cancer Research Conference: Molecular Basis for Targeted Therapy of Leukaemia
2006 RCPA Technical assiatance grant $3000 CIA
2003 Baxter travelling scholarship to present at the American Society of Haematology meeting in San Diego $2,000

K. INVITED ORAL PRESENTATIONS/EXTRAMURAL RESPONSIBILITIES

1. 2021 April- Whistler Global Virtual Summit on Hematologic Malignancies- Venetoclax in AML
2. 2021 April- Janssen virtual advisory board in AML- New assets for clinical development in AML
3. 2021 April- Virtual International Workshop in AML- Venetoclax resistance
4. 2021 April-Virtual meeting: Astellas China gilteritinib launch- Gilteritinib in AML
5. 2021 March-Medscape video- MRD monitoring in AML
6. 2021 March-Virtual meeting to MD Anderson Grand Rounds- AML therapy, an Australian perspective

7. 2021 March-Virtual meeting: Abbvie Singapore venetoclax launch- Venetoclax in unfit AML
8. 2021 March- Baylor College virtual symposium- Role of IDH inhibitors in MDS
9. 2020 October- Virtual meeting invited talk: Current and future clinical developments of BH3-mimetics in AML- Japan Society of Hematology
10. 2020 October- Virtual meeting invited talk: Current landscape in AML- Japan Society of Hematology- Abbvie symposium
11. 2020 October-Virtual meeting: Venetoclax in AML- Abbvie JAPAC launch meeting
12. 2020 October-Virtual meeting- invited plenary: New therapies in AML- ECHO symposium
13. 2020 October- Virtual meeting invited talk: Venetoclax in AML- Middle East Hematology Group
14. 2020 September- Virtual meeting invited talk: Venetoclax in AML- a game changer?- UK NCRN- AML academy
15. 2020 July- Virtual meeting brief communication: A phase 1b study of MBG453 in MDS/AML- European Society of Hematology
16. 2020 July- Virtual meeting invited talk: Defining the role of venetoclax in AML- European Society of Hematology
17. 2020 June-Virtual meeting: Maintenance therapy in AML- BMS launch meeting
18. 2020 June-Virtual meeting: Venetoclax in AML, predictors for response, resistance and combinations- Brazilian Hematology Society
19. 2020 June-Virtual meeting: Venetoclax in AML, predictors for response, resistance and combinations- Indian Hematology Society
20. 2020 June-Virtual meeting: VIALE-C- oral presentation- European Hematology Association
21. 2020 April-Virtual meeting: New therapies in AML- St Vincent's Hospital
22. 2020 April-Virtual meeting: New therapies in AML- Cabrini Hospital
23. 2020 April-Virtual meeting: Venetoclax in AML, predictors for response, resistance and combinations- Swedish Hematology Society
24. 2019 December- San Diego- Oral presentation: A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination withAzacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome- American Society of Hematology
25. 2019 December- San Diego- Late-Breaking Abstract Oral presentation: The QUAZAR AML Maintenance Trial: Results of an International Phase III,Randomized, Double-Blind, Placebo-Controlled Study of CC-486 in Patients withAcute Myeloid Leukemia (AML) in First Remission- American Society of Hematology
26. 2019 December- San Diego: What's new in AML?- American Society of Hematology- Abbvie symposium
27. 2019 December- San Diego: Emerging Maintenance Regimens in Newly-Diagnosed AML: Implications and Application- American Society of Hematology- Medscape Round Table
28. 2019 May- Barcelona- BH3-mimetic combinations in AML, International AML workshop (iwAML)

29. 2019 March- Daiichi Sankyo Symposium, Barcelona- Future Treatment Strategies in AML
30. 2019 March- Melbourne, Walter and Eliza Hall Institute of Medical Research- Future challenges in AML
31. 2019 February- Munich- Venetoclax and novel combinations, Acute Leukemias XVII
32. 2018 American Society of Hematology, San Diego, oral presentation- Molecular correlates of Venetoclax with Modified Intensive Chemotherapy in Fit, Treatment Naïve Elderly Patients
33. 2018 American Society of Hematology, San Diego, oral presentation - Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
34. 2018 October- Melbourne- New therapies in AML, Novartis Molecular and New Frontiers
35. 2018 October- New Frontiers in Medicine- Brisbane- FLT3 in AML
36. 2018 October- Molecular workshop- Brisbane- New therapies in AML
37. 2018 June- Stockholm- CAVEAT: Chemotherapy and Venetoclax in Elderly AML Trial
38. 2018 June- European Hematology Association, Stockholm- A Phase 1b Dose Escalation Study Examining Modified Intensive Chemotherapy in Fit, Treatment Naïve Elderly Patients
39. 2018 June- Educational symposium, EHA meeting, Stockholm- Targeting Epigenetics and Beyond
40. 2017 December- American Society of Hematology, Atlanta- Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes
41. 2017 December – MD Anderson Grand Rounds, Houston- BH3-mimetics in AML
42. 2017 October- Tokyo- BH3-mimetics in AML
43. 2017 October- Estoril- Targeting MCL1 in AML
44. 2017 October- Novartis molecular meeting- Current and future treatment of AML
45. 2017 September- GET meeting, Sydney- BH3-mimetics in AML
46. 2017 August- FRACP lecture- AML
47. 2017 July- Haem X meeting- Melbourne- IDH inhibitors in AML
48. 2017 July- Hudson Institute- Precision molecules to transform the therapeutic landscape in AML
49. 2017 July- HaemX educational meeting, Melbourne- Targeting IDH
50. 2017 June- Madrid- European Hematology Association- Updated Safety and Efficacy of a Phase 1/2 Study of Venetoclax + Low-Dose Cytarabine in Treatment-Naïve Patients with AML ≥65 Years and Unfit for Standard Induction Therapy
51. 2016 December- American Society of Hematology Oral Abstract- Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged ≥65 Years with Acute Myeloid Leukemia (AML), San Diego
52. 2016 December- American Society of Hematology Oral Abstract- Increased idarubicin dosage during consolidation therapy for adult acute myeloid leukemia improves leukemia-free survival, San Diego

53. 2016 December- American Society of Hematology Oral Abstract- Phase I Study of IDH305 in Advanced Malignancies Harboring IDH1R132 Mutations, San Diego
54. 2016 October- HAA Annual Conference Plenary Session- Role of BH3-mimetics in AML, Melbourne
55. 2016 September- International AML Platform Consortium- International AML workshop, Cardiff, Wales
56. 2016 August- Novel therapies in AML- GET national haematology symposium, Sydney
57. 2016 April- Molecular risk classification of AML- Malaysian Society of Haematology, Kuala Lumpur
58. 2016 April- Theraepeutic management of AML- Malaysian Society of Haematology, Kuala Lumpur
59. 2016 April- New therapies in AML- HOTT national symposium, Sydney
60. 2016 March- Targeting BCL2 in AML- Peter Mac Symposium, Melbourne
61. 2016 March- Clinical Spotlight: AML advances- New Directions in Leukaemia Research, Noosa, Qld
62. 2016 February- Current therapeutic directions in AML- Celgene Asia Pacific Advisory Committee, Guangzhou, China
63. 2015 September- Leukaemia Foundation of Australia National Annual Conference- AML therapy, Melbourne
64. 2015 August- Overview of the AML treatment landscape- Pfizer advisory board, Sydney
65. 2015 March- Evolution and management of myeloid neoplasms- Novartis GET meeting, Sydney
66. 2015 May-An international, phase 3, randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia in complete remission: the QASAR AML maintenance trial- poster ASCO, Chicago
67. 2014 August- Emerging trends in AML- Alfred Hospital Grand Rounds
68. 2014 August- New developments in AML- Austin Hospital
69. 2014 August- New developments in AML- Royal Children's Hospital
70. 2014 July- AML drug development summit, Celgene; La Jolla
71. 2014 July- New horizons in AML- Darwin Hospital Grand Rounds
72. 2014 June- AML and MDS- RACP education, Melbourne
73. 2014 June- Chair, AML drug development panel, Novartis LEAD summit; Montreal
74. 2014 April- "New developments in AML" St. Vincent's Hospital
75. 2014 February- Walter and Eliza Hall Institute of Medical Research "Evaluating drug activity in AML" Melbourne
76. 2014 February- Pathology Update "Clincal implication of molecular genetics in AML" Melbourne Convention Centre
77. 2014 Janurary- Combined Melbourne haematologists "ASH 2013: Update on targeted therapies in AML" Melbourne
78. 2014 December- Abbvie/Genentech ABT-199 advisory board for AML "Targeting survival pathways in AML" New Orleans

79. 2013 October- Presidential symposium HSANZ Australia “Dual targeting of AML survival pathways with PIK-75” Gold Coast
80. 2013 October- Royal Australasian College of Physicians “Sample size determination in clinical trials” Melbourne
81. 2013 October- Society of Hospital Pharmacists Australasia annual conference “Personalised care: where have we come from and where are we going” Melbourne
82. 2013 October- Leukaemia Foundation of Australia National Annual Conference “Introduction to AML” Melbourne
83. 2013 October- Monash Comprehensive Cancer Centre (MCCC) Southern Melbourne Cancer Forum “Taking research to the clinic” Melbourne
84. 2013 September- Leukaemia Foundation of Australia National Annual Conference- AML therapy, Melbourne
85. 2013 September- Human Genetics Society of Australasia South Australia Branch Symposium “New directions in AML therapy” Adelaide
86. 2013 August- International Society of Oncology Pharmacy Practitioners Australasian Regional Symposium “Understanding AML/APML” Melbourne
87. 2013 June- Leukaemia Foundation of Australia “New treatments in AML” Adelaide
88. 2013 June- Novartis National “GET” symposium “Molecular pathways in AML” Sydney Hilton, Sydney
89. 2013 May- Celgene Advisory board “AML registry and AZA-LBH589 update”, Berlin, Germany
90. 2013 April- Festchrift for Prof Haten Salem “Progress in AML” Alfred Hospital, Melbourne
91. 2013 March- Amgen drug development presentation, Melbourne
92. 2013 February- International symposium Acute Leukaemias XIV “Sorafenib induced killing of FLT3-ITD AML mediated by pro-apoptotic Bim” Munich, Germany
93. 2012 December- AMGEN headquarters “Strategies for targeting AML” Thousand Oaks, California
94. 2012 November- Alfred nursing education day “AML”, Melbourne
95. 2012 October- Bristol Myers Squibb New Frontiers in Therapeutic Options national symposium “Acute Myeloid Leukaemia”, Melbourne
96. 2012 October- HSANZ Australia “Clinically relevant molecular tests in acute leukaemias”, Melbourne Convention Centre
97. 2012 October- Peter MacCallum Cancer Institute “Clinical challenges in AML”, Melbourne
98. 2012 October- Leukaemia Foundation of Australia National Convention, Melbourne
99. 2012 August- Walter and Eliza Hall Institute of Medical Research Chemical Biology Division “Clinical drug development hurdles in AML”, Melbourne
100. 2012 June- Austin hospital haematology department seminar “Identifying poor risk in AML”
101. 2012 June- Leukaemia Foundation of Australia “Clinical trials in AML” Adelaide

102. 2012 June- Monash Commercialization presentation “New strategies for identifying drug synergy” Melbourne
103. 2012 June- VTIS seminar “New directions in AML therapy” Melbourne
104. 2012 May- Novartis R&D symposium “Exploring new pathways in AML” Crown Promenade Hotel Melbourne
105. 2012 May- International Society of Oncology Pharmacy Practitioners X111 “Targeted Therapies in AML” Crown Conference Centre Melbourne
106. 2012 May- VMPGF update “Myeloid diseases” Sale Hospital
107. 2012 May- St Vincent’s Hospital seminar “Future strategies in AML”
108. 2012 April- Mastocytosis Society Meeting “Mastocytosis update” Port Macquarie
109. 2012 March- Pathology Update “Molecular genetics in AML” Sydney Convention Centre
110. 2011 Nov- NHMRC symposium “Two tales of translation” Canberra
111. 2011 Nov- Novartis trainee evening “AML update”
112. 2011 Dec- Celgene seminar “New therapeutic strategies in AML” La Jolla, California, USA
113. 2011 Oct- BMS educational symposium “Role of FLT3 inhibitors in AML”
114. 2011 Sept- Molecular Discussion Group Meeting “A Sequenom-based approach to prognostication in AML” Healthscope Clayton
115. 2011 July- Sunesis Voreloxin initiation meeting “Relapsed and refractory AML” Sydney
116. 2011 June- WEHI Research symposium “Clinical update in AML” Melbourne
117. 2011 July- Leukaemia Foundation Education day “Clinical trials update in AML” Darwin
118. 2011 April- Novartis GET meeting “New targeted therapies in AML.” Sydney
119. 2010 Nov- Asia Pacific Oncology Forum “Future directions in AML” Hong Kong
120. 2010 Oct- HSANZ “A clinical risk score in AML” Auckland
121. 2010 Oct- HSANZ “Novel therapies in AML” Auckland
122. 2010 Aug- HSANZ South Australia “Novel therapies in AML and New molecular targets in AML”
123. 2010 May- HSANZ Western Australia “New therapies in AML and Molecular diagnostics in AML”
124. 2010 April- World Congress of Internal Medicine “Trials and tribulations in AML” Melbourne
125. 2010 Oct- Novartis Global Advisory Board on mTOR inhibitors “The role of mTOR inhibitors in AML” Madrid
126. 2009 Nov- Leukaemia Foundation “Leukaemia directions in research” Melbourne
127. 2009 Nov- Royal Australasian College of Physicians “Update in haematology” Melbourne
128. 2009 Sept- Victorian Oncology Pharmacists Special Interest Group (VOPSIG) “Advancers in the treatment of AML” Melbourne
129. 2009 Aug- Amgen national haematology symposium “AML therapy: a new generation”

130. 2009 May- Novartis national haematology symposium “Treatment of patients with FLT3 mutations”
131. 2009 March- Roche 7th national annual HOTT symposium
132. 2009 Queensland haematology annual scientific meeting “Managing secondary AML”
133. 2009 Amgen Australia internal educational meeting “Acute leukaemia”
134. 2008 HOTT meeting “AML in the elderly” Sydney
135. 2007 Leukemia Foundation Educational DVD “Introduction to Acute Leukemia”
136. 2007 30th Annual Meeting of the Australasian Flow Cytometry Group “Translational aspects of CLL biology”
137. 2007 St. Vincent’s Institute of Research “Unlocking the Bcl-2 code for therapeutic benefit”
138. 2006 Australian Renal Society Meeting in Melbourne “Plasma cell dyscrasias”
139. 2005 Presidential Symposium speaker at the Haematology Society of Australia and New Zealand Meeting “Epstein Barr Virus Encodes a Bcl-2 Homologue (BHRF-1) That Causes Chemoresistance by A Novel Mechanism Immune from Mammalian Regulation” Sydney
140. 2005 4th International Workshop on Non-Hodgkin’s Lymphoma ”The molecular mechanisms underlying BH3 mimetic molecules targeting Bcl-2” Florida, USA
141. 2005 Alfred Hospital haematology department meeting “AML update”
142. 2005 PhD Seminar at the Walter and Eliza Hall Institute “Prospects for targeting Bcl-2 for cancer therapy”
143. 2004 Haematology Society of Australia meeting “Targeting chemoresistance: swinging the balance from cancer towards cure?” Melbourne
144. 2004 Haematology Society of Australia meeting “Immunohistological Detection Of Plasma Cell Microaggregates With CD138 Is A Predictor Of Earlier Relapse Post High-Dose Therapy For Plasma Cell Myeloma” Melbourne
145. 2004 Medical Oncology Group Australia “Overcoming chemoresistance for therapeutic benefit” Cairns
146. 2004 Royal Australasian College of Physicians Annual Scientific Meeting “Targeting chemoresistance: swinging the balance from cancer to cure” Canberra
147. 2003 Dec-American Society of Haematology meeting “Developing an immunocompetent mouse leukemia/lymphoma model for testing cytotoxic drug activity on Bcl-2 overexpressing tumors” San Diego
148. 2003 Haematology Society of Australia. Presidential Symposium presentation “Developing an immunocompetent mouse leukemia/lymphoma model for testing cytotoxic drug activity on Bcl-2 overexpressing tumors” Christchurch
149. 2003 Royal Australasian College of Physicians Annual Scientific Meeting “Development of Novel Anticancer Compounds Targeting Bcl-2” Hobart
150. 2001 Australian Flow Cytometry Group Meeting “Minimal Residual Disease Testing in Acute Leukaemia” Melbourne

L. BIBLIOGRAPHY

Scopus
EXPORT DATE:16 Jul 2022

Publications: 186
Citations: 15787
h-index: 43

Jonas, B.A., **Wei, A**.H., Recher, C., DiNardo, C.D., Jang, J.-H., Pratz, K., Panayiotidis, P., Montesinos, P., Yeh, S.-P., Ivanov, V., Fiedler, W., Yamauchi, T., Duan, Y., Mendes, W., Potluri, J., Tews, B., Ofran, Y.
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
(2022) American Journal of Hematology, 97 (8), pp. E299-E303.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131528200&doi=10.1002%2fajh.26600&partnerID=40&md5=558e9d88d9fd637af4fcc7e47cf4d713

Shah, M.V., Chhetri, R., Dholakia, R., Kok, C.H., Gangat, N., Alkhateeb, H.B., Al-Kali, A., Patnaik, M.M., Baranwal, A., Greipp, P.T., He, R., Begna, K.H., Tiong, I.S., **Wei, A**.H., Hiwase, D.
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms
(2022) American Journal of Hematology, 97 (8), pp. 1013-1022.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130713094&doi=10.1002%2fajh.26589&partnerID=40&md5=01470b6b1297d8a5e97017667f52d34f

Konopleva, M., Thirman, M.J., Pratz, K.W., Garcia, J.S., Recher, C., Pullarkat, V., Kantarjian, H.M., DiNardo, C.D., Dail, M., Duan, Y., Chyla, B., Potluri, J., Miller, C.L., **Wei, A**.H.
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
(2022) Clinical Cancer Research, 28 (13), pp. 2744-2752.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129297862&doi=10.1158%2f1078-0432.CCR-21-3405&partnerID=40&md5=3eb1d41f05989c0c320d32340e14241b

Parker, C., Berkovic, D., Ayton, D., Zomer, E., Liew, D., **Wei, A**.
Patient Perceived Financial Burden in Haematological Malignancies: A Systematic Review
(2022) Current Oncology, 29 (6), pp. 3807-3824.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131380337&doi=10.3390%2fcurroncol29060305&partnerID=40&md5=7d66a8d4f79d70303f0f4c7b627b5770

Roboz, G.J., Ravandi, F., **Wei, A**.H., Dombret, H., Thol, F., Voso, M.T., Schuh, A.C., Porkka, K., La Torre, I., Skikne, B., Zhong, J., Beach, C.L., Risueño, A., Menezes, D.L., Ossenkoppele, G., Döhner, H.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
(2022) Blood, 139 (14), pp. 2145-2155.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127514287&doi=10.1182%2fblood.2021013404&partnerID=40&md5=478e7317cb921f0f1fa51d1150c09f30

Pratz, K.W., Panayiotidis, P., Recher, C., Wei, X., Jonas, B.A., Montesinos, P., Ivanov, V., Schuh, A.C., DiNardo, C.D., Novak, J., Pejsa, V., Stevens, D., Yeh, S.-P., Kim, I., Turgut, M., Fracchiolla, N., Yamamoto, K., Ofran, Y., **Wei, A**.H., Bui, C.N., Benjamin, K., Kamalakar, R., Potluri, J., Mendes, W., Devine, J., Fiedler, W.

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
(2022) Blood Cancer Journal, 12 (4), art. no. 71, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128459880&doi=10.1038%2fs41408-022-00668-8&partnerID=40&md5=095146d7d0ba4cca59e644c6f058cbbe

Loo, S., **Wei, A**.H.
FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue
(2022) Haematologica, 107 (4), pp. 783-784.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127980648&doi=10.3324%2fhaematol.2021.279409&partnerID=40&md5=bc27259c3854ceb925c7a1602df6b262

Brackman, D., Eckert, D., Menon, R., Salem, A.H., Potluri, J., Smith, B.D., **Wei, A**.H., Hayslip, J., Miles, D., Mensing, S., Gopalakrishnan, S., Zha, J.
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy
(2022) Hematological Oncology, 40 (2), pp. 269-279.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124579943&doi=10.1002%2fhon.2964&partnerID=40&md5=5f4b60b1c32a30976f18cecf29dae631

Garcia-Manero, G., Döhner, H., **Wei, A**.H., La Torre, I., Skikne, B., Beach, C.L., Santini, V.
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies
(2022) Clinical Lymphoma, Myeloma and Leukemia, 22 (4), pp. 236-250.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118733472&doi=10.1016%2fj.clml.2021.09.021&partnerID=40&md5=cf6e294df59b8a31dee906b7f76d1059

Blombery, P., Lew, T.E., Dengler, M.A., Thompson, E.R., Lin, V.S., Chen, X., Nguyen, T., Panigrahi, A., Handunnetti, S.M., Carney, D.A., Westerman, D.A., Tam, C.S., Adams, J.M., **Wei, A**.H., Huang, D.C.S., Seymour, J.F., Roberts, A.W., Anderson, M.A.
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
(2022) Blood, 139 (8), pp. 1198-1207.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125129752&doi=10.1182%2fblood.2021012775&partnerID=40&md5=6ec62453b8657d6808d078aefb920270

Parker, C., Ayton, D., Zomer, E., Liew, D., Vassili, C., Fong, C.Y., **Wei, A**.
Erratum: Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system (Leukemia Research (2022) 112, (S0145212621017495), (10.1016/j.leukres.2021.106748))
(2022) Leukemia Research, 113, art. no. 106786, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123093943&doi=10.1016%2fj.leukres.2022.106786&partnerID=40&md5=6465d9fa698da245ae00fbda889040f4

Parker, C., **Wei, A**., Liew, D., Zomer, E., Ayton, D.
It doesn't stop at validation: patient reported outcome measures require ongoing and iterative development
(2022) Supportive Care in Cancer, 30 (2), pp. 995-998.

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115104650&doi=10.1007%2fs00520-021-06553-7&partnerID=40&md5=62243db49733afe36e35505204a21f21

Tedjaseputra, A., Kuzich, J.A., Thiagarajah, N., Teh, T.-C., McClelland, J., Rahman, M., Brook, R., Chua, C.C., Ong, D.M., Tan, S.-Y., Filshie, R., Fong, C.Y., Fedele, P., Bajel, A., Shortt, J., **Wei, A**.H.
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic
(2022) Leukemia and Lymphoma, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132693556&doi=10.1080%2f10428194.2022.2087065&partnerID=40&md5=115c462dab823a1131ab30ceb0037868

Wei, A.H., Seymour, J.F.
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes
(2022) British Journal of Haematology, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129703966&doi=10.1111%2fbjh.18240&partnerID=40&md5=3e7a8876344ba4b4106239e1a64a9219

DiNardo, C.D., Hochhaus, A., Frattini, M.G., Yee, K., Zander, T., Krämer, A., Chen, X., Ji, Y., Parikh, N.S., Choi, J., **Wei, A**.H.
A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
(2022) Journal of Cancer Research and Clinical Oncology, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127383350&doi=10.1007%2fs00432-022-03983-6&partnerID=40&md5=0eeadc724d3f3308af43d44790fb5115

Kadia, T.M., **Wei, A**.H.
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia: How Should We Use Currently Available Agents?
(2022) Cancer Journal (United States), 28 (1), pp. 67-72.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123745521&doi=10.1097%2fPPO.0000000000000574&partnerID=40&md5=4925bf3aacd0abaaab4e4a75a6b9b94c

Roboz, G.J., Yee, K., Verma, A., Borthakur, G., de la Fuente Burguera, A., Sanz, G., Mohammad, H.P., Kruger, R.G., Karpinich, N.O., Ferron-Brady, G., Acusta, A., Del Buono, H., Collingwood, T., Ballas, M., Dhar, A., **Wei, A**.H.
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
(2022) Leukemia and Lymphoma, 63 (2), pp. 463-467.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121580662&doi=10.1080%2f10428194.2021.2012667&partnerID=40&md5=55644ca55cc95b574dc2e8cfb923a54e

Parker, C., Ayton, D., Zomer, E., Liew, D., Vassili, C., Fong, C.Y., **Wei, A**.
Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system
(2022) Leukemia Research, 112, art. no. 106748, .

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119127970&doi=10.1016%2fj.leukres.2021.106748&partnerID=40&md5=66e3c0df8bdb815beff13055083994a0

Greenwood, M., Trahair, T., Sutton, R., Osborn, M., Kwan, J., Mapp, S., Howman, R., Anazodo, A., Wylie, B., D'Rozario, J., Hertzberg, M., Irving, I., Yeung, D., Coyle, L., Jager, A., Engeler, D., Venn, N., Frampton, C., **Wei, A**.H., Bradstock, K., Dalla-Pozza, L.
An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL
(2021) Blood Advances, 5 (24), pp. 5574-5583.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122394235&doi=10.1182%2fbloodadvances.2021005576&partnerID=40&md5=76dc171e655240d46011f20580684bb0

Tiong, I.S., Dillon, R., Ivey, A., Kuzich, J.A., Thiagarajah, N., Sharplin, K.M., Kok, C.H., Tedjaseputra, A., Rowland, J.P., Grove, C.S., Abro, E., Shortt, J., Hiwase, D.K., Bajel, A., Potter, N.E., Smith, M.L., Hemmaway, C.J., Thomas, A., Gilkes, A.F., Russell, N.H., **Wei, A**.H.
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
(2021) Blood Advances, 5, pp. 5107-5111.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121721973&doi=10.1182%2fbloodadvances.2021005455&partnerID=40&md5=da5ca7a31b542596cace384f9b3635fe

Roboz, G.J., Döhner, H., Pocock, C., Dombret, H., Ravandi, F., Jang, J.H., Selleslag, D., Mayer, J., Martens, U.M., Liesveld, J., Bernal, T., Wang, M.C., Yu, P., Shi, L., Guo, S., Torre, I.L., Skikne, B., Dong, Q., Braverman, J., Nehme, S.A., Beach, C.L., **Wei, A**.H.
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial
(2021) Haematologica, 106 (12), pp. 3240-3244.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120738327&doi=10.3324%2fhaematol.2021.279174&partnerID=40&md5=28ff0d9f89bb360a3e1fe931cd3289f0

Kantarjian, H., Short, N.J., DiNardo, C., Stein, E.M., Daver, N., Perl, A.E., Wang, E.S., **Wei, A**., Tallman, M.
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
(2021) The Lancet Haematology, 8 (12), pp. e922-e933.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119606704&doi=10.1016%2fS2352-3026%2821%2900270-2&partnerID=40&md5=e7a03687a1721ea71fadaad39f38316b

Ravandi, F., Roboz, G.J., **Wei, A**.H., Döhner, H., Pocock, C., Selleslag, D., Montesinos, P., Sayar, H., Musso, M., Figuera-Alvarez, A., Safah, H., Tse, W., Sohn, S.K., Hiwase, D., Chevassut, T., Pierdomenico, F., La Torre, I., Skikne, B., Bailey, R., Zhong, J., Beach, C.L., Dombret, H.
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
(2021) Journal of Hematology and Oncology, 14 (1), art. no. 133, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113742847&doi=10.1186%2fs13045-021-01142-x&partnerID=40&md5=69e9fb3aa52b970e76c1d91028725890

Parker, C., Liew, D., Ademi, Z., Owen, A.J., Ayton, D., **Wei, A**., Zomer, E.

Estimating the Productivity Impact of Acute Myeloid Leukemia in Australia between 2020 and 2029, Using a Novel Work Utility Measure: The Productivity-Adjusted Life Year (PALY)
(2021) JCO Oncology Practice, 17 (11), pp. E1803-E1810.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121955785&doi=10.1200%2fOP.20.00904&partnerID=40&md5=c23a34dc6aad99e0bb1174854875ef60

Nguyen, P.C., Manos, K., Fong, C.Y., Schwarer, A.P., Tiong, I.S., **Wei, A**.H., Kliman, D., Curtis, D.J.
Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission
(2021) Internal Medicine Journal, 51 (11), pp. 1954-1958.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119214889&doi=10.1111%2fimj.15564&partnerID=40&md5=e28397991ebb0e2660f8aeb47874ed7f

Bosc, C., Saland, E., Bousard, A., Gadaud, N., Sabatier, M., Cognet, G., Farge, T., Boet, E., Gotanègre, M., Aroua, N., Mouchel, P.-L., Polley, N., Larrue, C., Kaphan, E., Picard, M., Sahal, A., Jarrou, L., Tosolini, M., Rambow, F., Cabon, F., Nicot, N., Poillet-Perez, L., Wang, Y., Su, X., Fovez, Q., Kluza, J., Argüello, R.J., Mazzotti, C., Avet-Loiseau, H., Vergez, F., Tamburini, J., Fournié, J.-J., Tiong, I.S., **Wei, A**.H., Kaoma, T., Marine, J.-C., Récher, C., Stuani, L., Joffre, C., Sarry, J.-E.
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia
(2021) Nature Cancer, 2 (11), pp. 1204-1223.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118842657&doi=10.1038%2fs43018-021-00264-y&partnerID=40&md5=3cef87b51a97011c3df7e83dbd4e3cb1

DiNardo, C.D., Schuh, A.C., Stein, E.M., Montesinos, P., **Wei, A**.H., de Botton, S., Zeidan, A.M., Fathi, A.T., Kantarjian, H.M., Bennett, J.M., Frattini, M.G., Martin-Regueira, P., Lersch, F., Gong, J., Hasan, M., Vyas, P., Döhner, H.
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
(2021) The Lancet Oncology, 22 (11), pp. 1597-1608.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118342942&doi=10.1016%2fS1470-2045%2821%2900494-0&partnerID=40&md5=4d8a0454adad4f2c223c864bee29eed7

Wei, A.H., Panayiotidis, P., Montesinos, P., Laribi, K., Ivanov, V., Kim, I., Novak, J., Stevens, D.A., Fiedler, W., Pagoni, M., Bergeron, J., Ting, S.B., Hou, J.-Z., Anagnostopoulos, A., McDonald, A., Murthy, V., Yamauchi, T., Wang, J., Chyla, B., Sun, Y., Jiang, Q., Mendes, W., Hayslip, J., DiNardo, C.D.
Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (Blood Cancer Journal, (2021), 11, 10, (163), 10.1038/s41408-021-00555-8)
(2021) Blood Cancer Journal, 11 (10), art. no. 171, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118352430&doi=10.1038%2fs41408-021-00565-6&partnerID=40&md5=2a46fd9e374f4bbcc107581606042df0

Yeoh, Z.H., Bajel, A., **Wei, A**.H.
New drugs bringing new challenges to AML: A brief review
(2021) Journal of Personalized Medicine, 11 (10), art. no. 1003, .

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85117230534&doi=10.3390%2fjpm11101003&partnerID=40&md5=9b3cb2a4ce44239e9223a862f177b744

Wei, A.H., Panayiotidis, P., Montesinos, P., Laribi, K., Ivanov, V., Kim, I., Novak, J., Stevens, D.A., Fiedler, W., Pagoni, M., Bergeron, J., Ting, S.B., Hou, J.-Z., Anagnostopoulos, A., McDonald, A., Murthy, V., Yamauchi, T., Wang, J., Chyla, B., Sun, Y., Jiang, Q., Mendes, W., Hayslip, J., DiNardo, C.D.
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
(2021) Blood Cancer Journal, 11 (10), art. no. 163, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116375840&doi=10.1038%2fs41408-021-00555-8&partnerID=40&md5=aba963c27c825589b50ad431b2dfc5c8

Roberts, A.W., **Wei, A**.H., Huang, D.C.S.
BCL2 and MCL1 inhibitors for hematologic malignancies
(2021) Blood, 138 (13), pp. 1120-1136.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116055602&doi=10.1182%2fblood.2020006785&partnerID=40&md5=607d0ac01b74b7bab36646b1befc002f

Wei, A.H., Roboz, G.J., Kantarjian, H.M.
Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia
(2021) Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39 (25), pp. 2742-2748.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115440439&doi=10.1200%2fJCO.21.00080&partnerID=40&md5=94f1d43b1a2bc7a17de97303fc020c33

Yamauchi, T., Yoshida, C., Usuki, K., Takada, S., Matsumura, I., Dobashi, N., Miyazaki, Y., Miyamoto, T., Iida, H., Asou, N., Kuroda, J., Ichikawa, S., Komatsu, N., Mendes, W., Honda, H., Okubo, S., Kurokawa, M., Jiang, Q., **Wei, A**., Ishizawa, K.
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
(2021) Japanese Journal of Clinical Oncology, 51 (9), pp. 1372-1382.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114984551&doi=10.1093%2fjjco%2fhyab112&partnerID=40&md5=ec46d80a49b4c110bcfc92af194aa54b

de Botton, S., BrandWein, J.M., **Wei, A**.H., Pigneux, A., Quesnel, B., Thomas, X., Legrand, O., Recher, C., Chantepie, S., Hunault-Berger, M., Boissel, N., Nehme, S.A., Frattini, M.G., Tosolini, A., Marion-Gallois, R., Wang, J.J., Cameron, C., Siddiqui, M., Hutton, B., Milkovich, G., Stein, E.M.
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
(2021) Cancer Medicine, 10 (18), pp. 6336-6343.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113743506&doi=10.1002%2fcam4.4182&partnerID=40&md5=ac2f0716a62a9124aea2e7dea96b4bfe

Kantarjian, H.M., Short, N.J., Fathi, A.T., Marcucci, G., Ravandi, F., Tallman, M., Wang, E.S., **Wei, A**.H.
Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
(2021) Clinical Lymphoma, Myeloma and Leukemia, 21 (9), pp. 580-597.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108975213&doi=10.1016%2fj.clml.2021.05.016&partnerID=40&md5=3adaa5095ce53376e5c7778d78b5291c

Döhner, H., **Wei, A**.H., Löwenberg, B.
Towards precision medicine for AML
(2021) Nature Reviews Clinical Oncology, 18 (9), pp. 577-590.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106007844&doi=10.1038%2fs41571-021-00509-w&partnerID=40&md5=7274fe9cf558f050fe21d66991fb491d

Larson, R.A., Mandrekar, S.J., Huebner, L.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., Thiede, C., Prior, T.W., Döhner, K., Marcucci, G., Voso, M.T., Klisovic, R.B., Galinsky, I., **Wei, A**.H., Sierra, J., Sanz, M.A., BrandWein, J.M., de Witte, T., Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Krauter, J., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Gathmann, I., Döhner, H., Stone, R.M.
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
(2021) Leukemia, 35 (9), pp. 2539-2551.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102027088&doi=10.1038%2fs41375-021-01179-4&partnerID=40&md5=178055377b6edd105927852be47cd68f

Wei, A.H.
Fitness for intensive chemotherapy: a continuing conundrum
(2021) Blood, 138 (5), pp. 356-358.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111744002&doi=10.1182%2fblood.2021011361&partnerID=40&md5=f4263b6788b2ccdc4337dc0afff900a1

Wei, A.H., Ribera, J.-M., Larson, R.A., Ritchie, D., Ghobadi, A., Chen, Y., Anderson, A., Dos Santos, C.E., Franklin, J., Kantarjian, H.
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
(2021) Leukemia, 35 (8), pp. 2220-2231.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100356519&doi=10.1038%2fs41375-020-01089-x&partnerID=40&md5=a01d14af0b426f64a06a4a99ddc8a444

Bryant, J., Carey, M., Sanson-Fisher, R., Turon, H., **Wei, A**., Kuss, B.
The Patients' Perspective: Hematological Cancer Patients' Experiences of Adverse Events as Part of Care
(2021) Journal of Patient Safety, 17 (5), pp. E387-E392.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015700863&doi=10.1097%2fPTS.0000000000000347&partnerID=40&md5=a7594d031054b37ee726904216b24b0b

Batchelor, R., Thomas, C., Gardiner, B.J., Lee, S.J., Fleming, S., **Wei, A**., Coutsouvelis, J., Ananda-Rajah, M.
When Azoles Cannot Be Used: The Clinical Effectiveness of Intermittent Liposomal Amphotericin Prophylaxis in Hematology Patients
(2021) Open Forum Infectious Diseases, 8 (7), art. no. ofab113, .

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112474596&doi=10.1093%2fofid%2fofab113&partnerID=40&md5=78cadac0fa146be07a7a84238dafe776

Kipp, D., H **Wei, A**.
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes
(2021) Future Oncology, 17 (20), pp. 2563-2571.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108123786&doi=10.2217%2ffon-2020-1318&partnerID=40&md5=6cc2b3fe6bf1a031218d58eca289b7b3

Corboy, G., Othman, J., Lee, L., **Wei, A**., Ivey, A., Blombery, P., Agarwal, R., Fong, C., Brown, A., Scott, H., Grove, C., Louw, A., Enjeti, A., Iland, H., Paul, C., Bohlander, S., Kakadia, P., Horan, M., Stevenson, W.
Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative
(2021) Pathology, 53 (4), pp. 487-492.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097060876&doi=10.1016%2fj.pathol.2020.08.019&partnerID=40&md5=db9267b978425b04c493330537cab124

Thijssen, R., Diepstraten, S.T., Moujalled, D., Chew, E., Flensburg, C., Shi, M.X., Dengler, M.A., Litalien, V., MacRaild, S., Chen, M., Anstee, N.S., Reljić, B., Gabriel, S.S., Djajawi, T.M., Riffkin, C.D., Aubrey, B.J., Chang, C., Tai, L., Xu, Z., Morley, T., Pomilio, G., Bruedigam, C., Kallies, A., Stroud, D.A., Bajel, A., Kluck, R.M., Lane, S.W., Schoumacher, M., Banquet, S., Majewski, I.J., Strasser, A., Roberts, A.W., Huang, D.C.S., Brown, F.C., Kelly, G.L., **Wei, A**.H.
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
(2021) Blood, 137 (20), pp. 2721-2735.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107086894&doi=10.1182%2fblood.2020010167&partnerID=40&md5=01f66c6e50fbfb3bde1411f65c738042

McCaughan, G., Di Ciaccio, P., Ananda-Rajah, M., Gilroy, N., MacIntyre, R., Teh, B., Weinkove, R., Curnow, J., Szer, J., Enjeti, A.K., Ross, D.M., Mulligan, S., Trotman, J., Dickinson, M., Quach, H., Choi, P., Polizzotto, M.N., Tam, C.S., Ho, P.J., Ku, M., Gregory, G., Gangatharan, S., Hapgood, G., Cochrane, T., Cheah, C., Gibbs, S., **Wei, A**., Johnston, A., Greenwood, M., Prince, H.M., Latimer, M., Berkahn, L., Wight, J., Armytage, T., Hamad, N.
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement
(2021) Internal Medicine Journal, 51 (5), pp. 763-768.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107017237&doi=10.1111%2fimj.15247&partnerID=40&md5=9fab2749133bf152fc0c1bd253241c6f

Hu, Y., Jin, J., Zhang, Y., Hu, J.D., Li, J.M., Wei, X.D., Gao, S.J., Zha, J.H., Jiang, Q., Wu, J., Mendes, W., **Wei, A**.H., Wang, J.X.
Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial
(2021) Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 42 (4), pp. 288-294.

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105839915&doi=10.3760%2fcma.j.issn.0253-2727.2021.04.004&partnerID=40&md5=3c94ecdab91ebd2b276e15b9c89b04ed

Wei, A.H., Döhner, H., Roboz, G.J.
Oral Azacitidine Maintenance for Acute Myeloid Leukemia. Reply
(2021) The New England journal of medicine, 384 (13), p. e51.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103744531&doi=10.1056%2fNEJMc2101283&partnerID=40&md5=d44e0733d8bd3012919cbeb7b166bb59

Wei, A.H., Daver, N.
Taking aim at IDH in fitter patients with AML
(2021) Blood, 137 (13), pp. 1706-1707.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103645690&doi=10.1182%2fblood.2020009361&partnerID=40&md5=bc0517c849f6d75ad4a419639a6431d2

Sharplin, K., Wee, L.Y.A., Singhal, D., Edwards, S., Danner, S., Lewis, I., Thomas, D., **Wei, A**., Yong, A.S.M., Hiwase, D.K.
Outcomes and health care utilization of older patients with acute myeloid leukemia
(2021) Journal of Geriatric Oncology, 12 (2), pp. 243-249.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088791225&doi=10.1016%2fj.jgo.2020.07.002&partnerID=40&md5=d95958db83742ab700730eb67d68cc71

Tiong, I.S., Dillon, R., Ivey, A., Teh, T.-C., Nguyen, P., Cummings, N., Taussig, D.C., Latif, A.-L., Potter, N.E., Runglall, M., Russell, N.H., Raj, K., Schwarer, A.P., Fong, C.Y., Grigg, A.P., **Wei, A**.H.
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia
(2021) British Journal of Haematology, 192 (6), pp. 1026-1030.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085567944&doi=10.1111%2fbjh.16722&partnerID=40&md5=1d8ae3fb4b6facc49db93fa8395b740f

Parker, C., Berkovic, D., **Wei, A**., Zomer, E., Liew, D., Ayton, D.
'If I don't work, I don't get paid': An Australian qualitative exploration of the financial impacts of acute myeloid leukaemia
(2021) Health and Social Care in the Community, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118847845&doi=10.1111%2fhsc.13642&partnerID=40&md5=450120e05bed93751c80cbbc1526889e

Loo, S., **Wei, A**.H.
Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?
(2021) Leukemia and Lymphoma, 62 (13), pp. 3073-3077.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112596423&doi=10.1080%2f10428194.2021.1961243&partnerID=40&md5=d9e0337a635eff072afc3ace5c5d62f0

Chua, C.C., **Wei, A**.H.

Future Developments: Novel Agents
(2021) Hematologic Malignancies, pp. 293-315.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106532449&doi=10.1007%2f978-3-030-72676-8_17&partnerID=40&md5=3ab20ca775a5f320542b3a0613ed7974

Bjelosevic, S., Gruber, E., Newbold, A., Shembrey, C., Devlin, J.R., Hogg, S.J., Kats, L., Todorovski, I., Fan, Z., Abrehart, T.C., Pomilio, G., **Wei, A**., Gregory, G.P., Vervoort, S.J., Brown, K.K., Johnstone, R.W.
Serine biosynthesis is a metabolic vulnerability in flt3-itd–driven acute myeloid leukemia
(2021) Cancer Discovery, 11 (6), pp. 1582-1599.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102488037&doi=10.1158%2f2159-8290.CD-20-0738&partnerID=40&md5=51765750be386d9b5f7dccfd40c7c3b6

Loh, J.B.E., Walker, P., Avery, S., Patil, S., Spencer, A., **Wei, A**., Fleming, S.
Double trouble or a silver lining? A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML)
(2021) Leukemia and Lymphoma, 62 (2), pp. 489-491.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092618089&doi=10.1080%2f10428194.2020.1832663&partnerID=40&md5=d57cbf22b8df846cdfcca6c429d28c67

Montesinos, P., Roboz, G.J., Bulabois, C.-E., Subklewe, M., Platzbecker, U., Ofran, Y., Papayannidis, C., Wierzbowska, A., Shin, H.J., Doronin, V., Deneberg, S., Yeh, S.-P., Ozcan, M.A., Knapper, S., Cortes, J., Pollyea, D.A., Ossenkoppele, G., Giralt, S., Döhner, H., Heuser, M., Xiu, L., Singh, I., Huang, F., Larsen, J.S., **Wei, A**.H.
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
(2021) Leukemia, 35 (1), pp. 62-74.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081676423&doi=10.1038%2fs41375-020-0773-5&partnerID=40&md5=02f89b84eb39d5fd5682a44a1b49d166

Wei, A.H., Döhner, H., Pocock, C., Montesinos, P., Afanasyev, B., Dombret, H., Ravandi, F., Sayar, H., Jang, J.-H., Porkka, K., Selleslag, D., Sandhu, I., Turgut, M., Giai, V., Ofran, Y., Çakar, M.K., de Sousa, A.B., Rybka, J., Frairia, C., Borin, L., Beltrami, G., Čermák, J., Ossenkoppele, G.J., la Torre, I., Skikne, B., Kumar, K., Dong, Q., Beach, C.L., Roboz, G.J., the QUAZAR AML-001 Trial Investigators
Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission
(2020) New England Journal of Medicine, 383 (26), pp. 2526-2537.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098647650&doi=10.1056%2fNEJMoa2004444&partnerID=40&md5=b2db03634cce89261b4ee3dc3b259ca1

Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., **Wei, A**., Higgins, B., Ott, M., Mascarenhas, J., Andreeff, M.
MDM2 inhibition: an important step forward in cancer therapy
(2020) Leukemia, 34 (11), pp. 2858-2874.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087796553&doi=10.1038%2fs41375-020-0949-z&partnerID=40&md5=24091e1823bdf34774616b6a457e19d6

Wei, A.H., Roberts, A.W., Spencer, A., Rosenberg, A.S., Siegel, D., Walter, R.B., Caenepeel, S., Hughes, P., McIver, Z., Mezzi, K., Morrow, P.K., Stein, A.
Targeting MCL-1 in hematologic malignancies: Rationale and progress

(2020) Blood Reviews, 44, art. no. 100672, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081954593&doi=10.1016%2fj.blre.2020.100672&partnerID=40&md5=c017577975632c83c85f1f5abbf5f8a6

Chua, C.C., Roberts, A.W., Reynolds, J., Fong, C.Y., Ting, S.B., Salmon, J.M., MacRaild, S., Ivey, A., Tiong, I.S., Fleming, S., Brown, F.C., Loo, S., Majewski, I.J., Bohlander, S.K., **Wei, A**.H.
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined with Modified Intensive Chemotherapy
(2020) Journal of Clinical Oncology, 38 (30), pp. 3506-3517.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092643597&doi=10.1200%2fJCO.20.00572&partnerID=40&md5=28dad83917d9eb312d278e4b078b87ba

Morrish, E., Copeland, A., Moujalled, D.M., Powell, J.A., Silke, N., Lin, A., Jarman, K.E., Sandow, J.J., Ebert, G., Mackiewicz, L., Beach, J.A., Christie, E.L., Lewis, A.C., Pomilio, G., Fischer, K.C., MacPherson, L., Bowtell, D.D.L., Webb, A.I., Pellegrini, M., Dawson, M.A., Pitson, S.M., **Wei, A**.H., Silke, J., Brumatti, G.
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
(2020) Blood Advances, 4 (20), pp. 5062-5077.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090607414&doi=10.1182%2fBLOODADVANCES.2020001576&partnerID=40&md5=ffccfd1d98bade5ad2866acf30fcc74a

Voso, M.T., Larson, R.A., Jones, D., Marcucci, G., Prior, T., Krauter, J., Heuser, M., Lavorgna, S., Nomdedeu, J., Geyer, S.M., Walker, A., **Wei, A**.H., Sierra, J., Sanz, M.A., BrandWein, J.M., de Witte, T.M., Jansen, J.H., Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Schlenk, R.F., Ganser, A., Amadori, S., Cheng, Y., Chen, Y., Pallaud, C., Du, L., Piciocchi, A., Ehninger, G., Byrd, J., Thiede, C., Döhner, K., Stone, R.M., Döhner, H., Bloomfield, C.D., Lo-Coco, F.
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: A subanalysis from the RATIFY trial
(2020) Blood Advances, 4 (19), pp. 4945-4954.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096194729&doi=10.1182%2fBLOODADVANCES.2020002904&partnerID=40&md5=f2a5308e07fe4b4682f8fe78cd6dff15

Daver, N., **Wei, A**.H., Pollyea, D.A., Fathi, A.T., Vyas, P., DiNardo, C.D.
New directions for emerging therapies in acute myeloid leukemia: the next chapter
(2020) Blood Cancer Journal, 10 (10), art. no. 107, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094678035&doi=10.1038%2fs41408-020-00376-1&partnerID=40&md5=5563dbca35d538b1cc7859da8a092706

McManus, J.F., Nguyen, N.-Y.N., Davey, R.A., MacLean, H.E., Pomilio, G., McCormack, M.P., Chiu, W.S., **Wei, A**.H., Zajac, J.D., Curtis, D.J.
Androgens stimulate erythropoiesis through the DNA-binding activity of the androgen receptor in non-hematopoietic cells
(2020) European Journal of Haematology, 105 (3), pp. 247-254.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084583400&doi=10.1111%2fejh.13431&partnerID=40&md5=025a9395ba581c3786636df4f8d6c03c

DiNardo, C.D., Jonas, B.A., Pullarkat, V., Thirman, M.J., Garcia, J.S., **Wei, A**.H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., Koller, E., Havelange, V., Leber, B., Esteve, J., Wang, J., Pejsa, V., Hájek, R., Porkka, K., Illés, Á., Lavie, D., Lemoli, R.M., Yamamoto, K., Yoon, S.-S., Jang, J.-H., Yeh, S.-P., Turgut, M., Hong, W.-J., Zhou, Y., Potluri, J., Pratz, K.W.
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
(2020) New England Journal of Medicine, 383 (7), pp. 617-629.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089407724&doi=10.1056%2fNEJMoa2012971&partnerID=40&md5=0b6cddfa4471d1e8249c7a710a5bacf0

Zeidan, A.M., Boddu, P.C., Patnaik, M.M., Bewersdorf, J.P., Stahl, M., Rampal, R.K., Shallis, R., Steensma, D.P., Savona, M.R., Sekeres, M.A., Roboz, G.J., DeAngelo, D.J., Schuh, A.C., Padron, E., Zeidner, J.F., Walter, R.B., Onida, F., Fathi, A., DeZern, A., Hobbs, G., Stein, E.M., Vyas, P., **Wei, A**.H., Bowen, D.T., Montesinos, P., Griffiths, E.A., Verma, A.K., Keyzner, A., Bar-Natan, M., Navada, S.C., Kremyanskaya, M., Goldberg, A.D., Al-Kali, A., Heaney, M.L., Nazha, A., Salman, H., Luger, S., Pratz, K.W., Konig, H., Komrokji, R., Deininger, M., Cirici, B.X., Bhatt, V.R., Silverman, L.R., Erba, H.P., Fenaux, P., Platzbecker, U., Santini, V., Wang, E.S., Tallman, M.S., Stone, R.M., Mascarenhas, J.
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
(2020) The Lancet Haematology, 7 (8), pp. e601-e612.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087508878&doi=10.1016%2fS2352-3026%2820%2930205-2&partnerID=40&md5=f0faec03ba6ff8183aa4056beae1b426

Moujalled, D.M., Hanna, D.T., Hediyeh-Zadeh, S., Pomilio, G., Brown, L., Litalien, V., Bartolo, R., Fleming, S., Chanrion, M., Banquet, S., Maragno, A.-L., Kraus-Berthier, L., Schoumacher, M., Mullighan, C.G., Georgiou, A., White, C.A., Lessene, G., Huang, D.C.S., Roberts, A.W., Geneste, O., Rasmussen, L., Davis, M.J., Ekert, P.G., **Wei, A**., Ng, A.P., Khaw, S.L.
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
(2020) Blood Advances, 4 (12), pp. 2762-2767.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086943107&doi=10.1182%2fbloodadvances.2019001416&partnerID=40&md5=07d102cb0f0a44fe721a2d447353cb30

Wei, A.H., Montesinos, P., Ivanov, V., DiNardo, C.D., Novak, J., Laribi, K., Kim, I., Stevens, D.A., Fiedler, W., Pagoni, M., Samoilova, O., Hu, Y., Anagnostopoulos, A., Bergeron, J., Hou, J.-Z., Murthy, V., Yamauchi, T., McDonald, A., Chyla, B., Gopalakrishnan, S., Jiang, Q., Mendes, W., Hayslip, J., Panayiotidis, P.
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
(2020) Blood, 135 (24), pp. 2137-2145.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085286405&doi=10.1182%2fBLOOD.2020004856&partnerID=40&md5=9c09eae706619f6ccb340829f189fe1e

Montesinos, P., Beckermann, B.M., Catalani, O., Esteve, J., Gamel, K., Konopleva, M.Y., Martinelli, G., Monnet, A., Papayannidis, C., Park, A., Récher, C., Rodríguez-Veiga, R., Röllig, C., Vey, N., **Wei, A**.H., Yoon, S.-S., Fenaux, P.
MIRROS: A randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
(2020) Future Oncology, 16 (13), pp. 807-815.

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084026683&doi=10.2217%2ffon-2020-0044&partnerID=40&md5=00ac739f211853a30178b42f0e54d1de

Brown, A.L., Arts, P., Carmichael, C.L., Babic, M., Dobbins, J., Chong, C.-E., Schreiber, A.W., Feng, J., Phillips, K., Wang, P.P.S., Ha, T., Homan, C.C., King-Smith, S.L., Rawlings, L., Vakulin, C., Dubowsky, A., Burdett, J., Moore, S., McKavanagh, G., Henry, D., Wells, A., Mercorella, B., Nicola, M., Suttle, J., Wilkins, E., Li, X.-C., Michaud, J., Brautigan, P., Cannon, P., Altree, M., Jaensch, L., Fine, M., Butcher, C., D'Andrea, R.J., Lewis, I.D., Hiwase, D.K., Papaemmanuil, E., Horwitz, M.S., Natsoulis, G., Rienhoff Jr, H.Y., Patton, N., Mapp, S., Susman, R., Morgan, S., Cooney, J., Currie, M., Popat, U., Bochtler, T., Izraeli, S., Bradstock, K., Godley, L.A., Kr¨amer, A., Fröhling, S., **Wei, A**.H., Forsyth, C., Fan, H.M., Poplawski, N.K., Hahn, C.N., Scott, H.S.
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML
(2020) Blood Advances, 4 (6), pp. 1131-1144.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082318605&doi=10.1182%2fbloodadvances.2019000901&partnerID=40&md5=f6b5b0124a04b9660d0b8a308160212d

Chua, C.C., Grigg, A., Singh, J., Droogleever, M.P., Zhang, L., Lim, A., Fong, C.Y., Ting, S.B., Schwarer, A., Tiong, I.S., **Wei, A**.H.
Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals
(2020) Leukemia and Lymphoma, 61 (4), pp. 848-854.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075431577&doi=10.1080%2f10428194.2019.1691192&partnerID=40&md5=8de4e4c11a3babaca18f607df4c075f4

DiNardo, C.D., Tiong, I.S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F.C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J.M., Glytsou, C., Fleming, S.A., Zhang, Q., Ma, H., Patel, K.P., Kornblau, S.M., Xu, Z., Chua, C.C., Chen, X., Blombery, P., Flensburg, C., Cummings, N., Aifantis, I., Kantarjian, H., Huang, D.C.S., Roberts, A.W., Majewski, I.J., Konopleva, M., **Wei, A**.H.
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
(2020) Blood, 135 (11), pp. 791-803.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081944313&doi=10.1182%2fBLOOD.2019003988&partnerID=40&md5=d619aafe261367a7653dfd66dc6f29c2

Döhner, K., Thiede, C., Jahn, N., Panina, E., Gambietz, A., Larson, R.A., Prior, T.W., Marcucci, G., Jones, D., Krauter, J., Heuser, M., Voso, M.T., Ottone, T., Nomdedeu, J.F., Mandrekar, S.J., Klisovic, R.B., **Wei, A**.H., Sierra, J., Sanz, M.A., BrandWein, J.M., De Witte, T., Jansen, J.H., Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Gathmann, I., Benner, A., Pallaud, C., Stone, R.M., Döhner, H., Bloomfield, C.D.
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
(2020) Blood, 135 (5), pp. 371-380.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078814998&doi=10.1182%2fblood.2019002697&partnerID=40&md5=71146659082c88c43e8234aca8d385f5

DiNardo, C.D., **Wei, A**.H.
How I treat acute myeloid leukemia in the era of new drugs
(2020) Blood, 135 (2), pp. 85-96.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077761236&doi=10.1182%2fblood.2019001239&partnerID=40&md5=bffd1362ae4c3ab0f9d491a6e1ae966d

Pollyea, D.A., Pratz, K., Letai, A., Jonas, B.A., **Wei, A**.H., Pullarkat, V., Konopleva, M., Thirman, M.J., Arellano, M., Becker, P.S., Chyla, B., Hong, W.-J., Jiang, Q., Potluri, J., DiNardo, C.D.
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study
(2020) American Journal of Hematology, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096690655&doi=10.1002%2fajh.26039&partnerID=40&md5=16f3c5d3ca65cbc4699d473311d19b95

Tiong, I.S., **Wei, A**.H.
New drugs creating new challenges in acute myeloid leukemia
(2019) Genes Chromosomes and Cancer, 58 (12), pp. 903-914.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064519748&doi=10.1002%2fgcc.22750&partnerID=40&md5=0d33d4e4993a9ab807c76230e0121bc8

Angenendt, L., Röllig, C., Montesinos, P., Martínez-Cuadrón, D., Barragan, E., García, R., Botella, C., Martínez, P., Ravandi, F., Kadia, T., Kantarjian, H.M., Cortes, J., Juliusson, G., Lazarevic, V., Höglund, M., Lehmann, S., Recher, C., Pigneux, A., Bertoli, S., Dumas, P.-Y., Dombret, H., Preudhomme, C., Micol, J.-B., Terré, C., Ráčil, Z., Novák, J., Žák, P., **Wei, A**.H., Tiong, I.S., Wall, M., Estey, E., Shaw, C., Exeler, R., Wagenführ, L., Stölzel, F., Thiede, C., Stelljes, M., Lenz, G., Mikesch, J.-H., Serve, H., Ehninger, G., Berdel, W.E., Kramer, M., Krug, U., Schliemann, C.
Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: A pooled analysis of individual patient data from nine international cohorts
(2019) Journal of Clinical Oncology, 37 (29), pp. 2632-2642.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072994068&doi=10.1200%2fJCO.19.00416&partnerID=40&md5=8668da2bbde29e6a86e74fd17f0be3ae

Wei, A.H., Roberts, A.W.
Polyclonal heterogeneity: The new norm for secondary clinical resistance to targeted monotherapy in relapsed leukemia?
(2019) Cancer Discovery, 9 (8), pp. 998-1000.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070792884&doi=10.1158%2f2159-8290.CD-19-0575&partnerID=40&md5=b2d749e58e72206d9103c3cf54b608fb

McKenzie, M.D., Ghisi, M., Oxley, E.P., Ngo, S., Cimmino, L., Esnault, C., Liu, R., Salmon, J.M., Bell, C.C., Ahmed, N., Erlichster, M., Witkowski, M.T., Liu, G.J., Chopin, M., Dakic, A., Simankowicz, E., Pomilio, G., Vu, T., Krsmanovic, P., Su, S., Tian, L., Baldwin, T.M., Zalcenstein, D.A., DiRago, L., Wang, S., Metcalf, D., Johnstone, R.W., Croker, B.A., Lancaster, G.I., Murphy, A.J., Naik, S.H., Nutt, S.L., Pospisil, V., Schroeder, T., Wall, M., Dawson, M.A., **Wei, A**.H., de Thé, H., Ritchie, M.E., Zuber, J., Dickins, R.A.
Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
(2019) Cell Stem Cell, 25 (2), pp. 258-272.e9.

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069555508&doi=10.1016%2fj.stem.2019.07.001&partnerID=40&md5=c7cd8c3eada3c94d3905297622c450d6

Srivastava, R., Cao, Z., Nedeva, C., Naim, S., Bachmann, D., Rabachini, T., Gangoda, L., Shahi, S., Glab, J., Menassa, J., Osellame, L., Nelson, T., Fernandez-Marrero, Y., Brown, F., **Wei, A**., Ke, F., O'Reilly, L., Doerflinger, M., Allison, C., Kueh, A., Ramsay, R., Smith, B.J., Mathivanan, S., Kaufmann, T., Puthalakath, H.
BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals
(2019) Proceedings of the National Academy of Sciences of the United States of America, 116 (31), pp. 15469-15474.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070790331&doi=10.1073%2fpnas.1904523116&partnerID=40&md5=1791974b4225fddb1ad7aacfa3446ee4

Dombret, H., Topp, M.S., Schuh, A.C., **Wei, A**.H., Durrant, S., Bacon, C.L., Tran, Q., Zimmerman, Z., Kantarjian, H.
Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia
(2019) Leukemia and Lymphoma, 60 (9), pp. 2214-2222.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063907065&doi=10.1080%2f10428194.2019.1576872&partnerID=40&md5=1c8608084a75ad962f2a4cfc820eb1a5

Savona, M.R., **Wei, A**.H.
Incorporating precision BH3 warheads into the offensive against acute myeloid leukemia
(2019) Journal of Clinical Oncology, 37 (21), pp. 1785-1789.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070056088&doi=10.1200%2fJCO.19.00400&partnerID=40&md5=3e82f39f04e53d01e9c537caa91d931a

Wei, A.H., Strickland, S.A., Hou, J.-Z., Fiedler, W., Lin, T.L., Walter, R.B., Enjeti, A., Tiong, I.S., Savona, M., Lee, S., Chyla, B., Popovic, R., Salem, A.H., Agarwal, S., Xu, T., Fakouhi, K.M., Humerickhouse, R., Hong, W.-J., Hayslip, J., Roboz, G.J.
Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib/II study
(2019) Journal of Clinical Oncology, 37 (15), pp. 1277-1284.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064512421&doi=10.1200%2fJCO.18.01600&partnerID=40&md5=a2c0a18ff8993729268d0e94dcce0843

Iacobucci, I., Wen, J., Meggendorfer, M., Choi, J.K., Shi, L., Pounds, S.B., Carmichael, C.L., Masih, K.E., Morris, S.M., Lindsley, R.C., Janke, L.J., Alexander, T.B., Song, G., Qu, C., Li, Y., Payne-Turner, D., Tomizawa, D., Kiyokawa, N., Valentine, M., Valentine, V., Basso, G., Locatelli, F., Enemark, E.J., Kham, S.K.Y., Yeoh, A.E.J., Ma, X., Zhou, X., Sioson, E., Rusch, M., Ries, R.E., Stieglitz, E., Hunger, S.P., **Wei, A**.H., To, L.B., Lewis, I.D., D'Andrea, R.J., Kile, B.T., Brown, A.L., Scott, H.S., Hahn, C.N., Marlton, P., Pei, D., Cheng, C., Loh, M.L., Ebert, B.L., Meshinchi, S., Haferlach, T., Mullighan, C.G.
Genomic subtyping and therapeutic targeting of acute erythroleukemia
(2019) Nature Genetics, 51 (4), pp. 694-704.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063892573&doi=10.1038%2fs41588-019-0375-1&partnerID=40&md5=e32ac4fce2fed8bca519c59c3b60d502

Moujalled, D.M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T.-C., Tiong, I.-S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E., Colland, F., Segal, D., Huang, D., Roberts, A.W., Maragno, A.L., Lessene, G., Geneste, O., **Wei, A**.H.
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
(2019) Leukemia, 33 (4), pp. 905-917.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053632112&doi=10.1038%2fs41375-018-0261-3&partnerID=40&md5=04d254c257ce580cbbc7f383d43a4c85

Wei, A.H.
Maintenance therapy for AML: Are we there yet?
(2019) Blood, 133 (13), pp. 1390-1392.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064138676&doi=10.1182%2fblood-2019-02-897579&partnerID=40&md5=b9f8b7f518f1b70729cd27805911bba6

Chua, C.C., Fleming, S., **Wei, A**.H.
Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome
(2019) Best Practice and Research: Clinical Haematology, 32 (1), pp. 3-12.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062970655&doi=10.1016%2fj.beha.2019.02.007&partnerID=40&md5=4fc3721baa864e19080fb08fad44551d

Marquis, M., Beaubois, C., Lavallée, V.-P., Abrahamowicz, M., Danieli, C., Lemieux, S., Ahmad, I., **Wei, A**., Ting, S.B., Fleming, S., Schwarer, A., Grimwade, D., Grey, W., Hills, R.K., Vyas, P., Russell, N., Sauvageau, G., Hébert, J.
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia (Blood Cancer Journal, (2018), 8, 8, (68), 10.1038/s41408-018-0103-6)
(2019) Blood Cancer Journal, 9 (3), art. no. 28, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062389453&doi=10.1038%2fs41408-019-0190-z&partnerID=40&md5=240e3824d393ec85a0742d3a84b61c9c

DiNardo, C.D., Pratz, K., Pullarkat, V., Jonas, B.A., Arellano, M., Becker, P.S., Frankfurt, O., Konopleva, M., **Wei, A**.H., Kantarjian, H.M., Xu, T., Hong, W.-J., Chyla, B., Potluri, J., Pollyea, D.A., Letai, A.
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
(2019) Blood, 133 (1), pp. 7-17.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058620841&doi=10.1182%2fblood-2018-08-868752&partnerID=40&md5=76c22005122f91b4bc6d418e3d028ef9

Merino, D., Kelly, G.L., Lessene, G., **Wei, A**.H., Roberts, A.W., Strasser, A.
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
(2018) Cancer Cell, 34 (6), pp. 879-891.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056857529&doi=10.1016%2fj.ccell.2018.11.004&partnerID=40&md5=7c42092bc0f8f0d27485053a503243c3

Caenepeel, S., Brown, S.P., Belmontes, B., Moody, G., Keegan, K.S., Chui, D., Whittington, D.A., Huang, X., Poppe, L., Cheng, A.C., Cardozo, M., Houze, J., Li, Y., Lucas, B., Paras, N.A., Wang, X., Taygerly, J.P., Vimolratana, M., Zancanella, M., Zhu, L., Cajulis, E., Osgood, T., Sun, J., Damon, L., Egan, R.K., Greninger, P., McClanaghan, J.D., Gong, J., Moujalled, D., Pomilio,

G., Beltran, P., Benes, C.H., Roberts, A.W., Huang, D.C., **Wei, A**., Canon, J., Coxon, A., Hughes, P.E.
AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies
(2018) Cancer Discovery, 8 (12), pp. 1582-1597.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056860831&doi=10.1158%2f2159-8290.CD-18-0387&partnerID=40&md5=dc2680224915c945e542ff1aa95b72db

Tiong, I.S., Reynolds, J., Bradstock, K.F., Seymour, J.F., **Wei, A**.H., on behalf of the Australasian Leukaemia & Lymphoma Group
Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies
(2018) Blood Cancer Journal, 8 (9), art. no. 84, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052927973&doi=10.1038%2fs41408-018-0121-4&partnerID=40&md5=0564e19c391c6bef076914c8cf746adb

Bloomfield, C.D., Estey, E., Pleyer, L., Schuh, A.C., Stein, E.M., Tallman, M.S., **Wei, A**.
Time to repeal and replace response criteria for acute myeloid leukemia?
(2018) Blood Reviews, 32 (5), pp. 416-425.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046116875&doi=10.1016%2fj.blre.2018.03.006&partnerID=40&md5=916f5b4f1c8459716983335de73fef95

Marquis, M., Beaubois, C., Lavallée, V.-P., Abrahamowicz, M., Danieli, C., Lemieux, S., Ahmad, I., **Wei, A**., Ting, S.B., Fleming, S., Schwarer, A., Grimwade, D., Grey, W., Hills, R.K., Vyas, P., Russell, N., Sauvageau, G., Hébert, J.
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
(2018) Blood Cancer Journal, 8 (8), art. no. 68, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050732684&doi=10.1038%2fs41408-018-0103-6&partnerID=40&md5=77496df72662c80df485d53a2cf9074d

Prabahran, A., Tacey, M., Fleming, S., **Wei, A**., Tate, C., Marlton, P., Wight, J., Grigg, A., Tuckfield, A., Szer, J., Ritchie, D., Chee, L.
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine
(2018) European Journal of Haematology, 101 (2), pp. 174-184.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050308569&doi=10.1111%2fejh.13089&partnerID=40&md5=93eaca4530ae9da1c8d11db3729c7428

Ong, D.M., Farrugia, H., **Wei, A**.
Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003–2014
(2018) Internal Medicine Journal, 48 (7), pp. 822-829.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049598232&doi=10.1111%2fimj.13714&partnerID=40&md5=5e511be9c5e00310522b87cadbc36b16

DiNardo, C.D., Pratz, K.W., Letai, A., Jonas, B.A., **Wei, A**.H., Thirman, M., Arellano, M., Frattini, M.G., Kantarjian, H., Popovic, R., Chyla, B., Xu, T., Dunbar, M., Agarwal, S.K., Humerickhouse, R., Mabry, M., Potluri, J., Konopleva, M., Pollyea, D.A.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
(2018) The Lancet Oncology, 19 (2), pp. 216-228.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042766499&doi=10.1016%2fS1470-2045%2818%2930010-X&partnerID=40&md5=898cc26bcf5143a11642d9c482a3e950

Teh, T.-C., Nguyen, N.-Y., Moujalled, D.M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A., Cummins, K., Lackovic, K., Blombery, P., Thompson, E., Ekert, P.G., Lessene, G., Glaser, S.P., Huang, D.C.S., Roberts, A.W., Guthridge, M.A., **Wei, A**.H.
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
(2018) Leukemia, 32 (2), pp. 303-312.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042304104&doi=10.1038%2fleu.2017.243&partnerID=40&md5=576389ca20a0b9cbba0b2558d6735f4c

Tiong, I.S., Tan, P., McManus, J., Cummings, N., Sadawarte, S., Catalano, J., Hills, R., **Wei, A**.
Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia
(2018) Leukemia and Lymphoma, 59 (2), pp. 493-496.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020444787&doi=10.1080%2f10428194.2017.1334122&partnerID=40&md5=89cdbe2e92a9f0a1bafcd7f8b581cdf4

Duarte, D., Hawkins, E.D., Akinduro, O., Ang, H., De Filippo, K., Kong, I.Y., Haltalli, M., Ruivo, N., Straszkowski, L., Vervoort, S.J., McLean, C., Weber, T.S., Khorshed, R., Pirillo, C., **Wei, A**., Ramasamy, S.K., Kusumbe, A.P., Duffy, K., Adams, R.H., Purton, L.E., Carlin, L.M., Lo Celso, C.
Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML
(2018) Cell Stem Cell, 22 (1), pp. 64-77.e6.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038843065&doi=10.1016%2fj.stem.2017.11.006&partnerID=40&md5=0f5145132e2436ed8b9846ea916df0c5

Wei, A.H., Tiong, I.S.
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
(2017) Blood, 130 (23), pp. 2469-2474.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037659226&doi=10.1182%2fblood-2017-08-784066&partnerID=40&md5=fc90079c697b54fd603657f505a01e44

Stone, R.M., Mandrekar, S.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., Thiede, C., Prior, T.W., Dohner, K., Marcucci, G., Lo-Coco, F., Klisovic, R.B., **Wei, A**., Sierra, J., Sanz, M.A., BrandWein, J.M., De Witte, T., Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Krauter, J., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Larson, R.A., Dohner, H.
Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation
(2017) New England Journal of Medicine, 377 (5), pp. 454-464.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85025432950&doi=10.1056%2fNEJMoa1614359&partnerID=40&md5=3b684f05c63a306c47977eefc400b242

Swords, R.T., Greenberg, P.L., **Wei, A**.H., Durrant, S., Advani, A.S., Hertzberg, M.S., Lewis, I.D., Rivera, G., Gratzinger, D., Fan, A.C., Felsher, D.W., Cortes, J.E., Watts, J.M., Yarranton, G.T., Walling, J.M., Lancet, J.E.
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012)
(2017) Leukemia Research, 59, p. 65.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020052613&doi=10.1016%2fj.leukres.2017.02.007&partnerID=40&md5=d180ad5cc1e51add4d9ad99539428158

Wei, A.H.
Accelerating early drug development: come on down under!
(2017) Annals of Oncology, 28 (7), pp. 1655-1657.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047315428&doi=10.1093%2fannonc%2fmdx101&partnerID=40&md5=18526c8ed15259cb13e04aa366492144

Hein, N., Cameron, D.P., Hannan, K.M., Nguyen, N.-Y.N., Fong, C.Y., Sornkom, J., Wall, M., Pavy, M., Cullinane, C., Diesch, J., Devlin, J.R., George, A.J., Sanij, E., Quin, J., Poortinga, G., Verbrugge, I., Baker, A., Drygin, D., Harrison, S.J., Rozario, J.D., Powell, J.A., Pitson, S.M., Zuber, J., Johnstone, R.W., Dawson, M.A., Guthridge, M.A., **Wei, A**., McArthur, G.A., Pearson, R.B., Hannan, R.D.
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population
(2017) Blood, 129 (21), pp. 2882-2895.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019716272&doi=10.1182%2fblood-2016-05-718171&partnerID=40&md5=48a2d55a565a23907041caa566059338

Bradstock, K.F., Link, E., Iulio, J.D., Szer, J., Marlton, P., **Wei, A**.H., Enno, A., Schwarer, A., Lewis, I.D., D'Rozario, J., Coyle, L., Cull, G., Campbell, P., Leahy, M.F., Hahn, U., Cannell, P., Tiley, C., Lowenthal, R.M., Moore, J., Cartwright, K., Cunningham, I., Taper, J., Grigg, A., Roberts, A.W., Benson, W., Hertzberg, M., Deveridge, S., Rowlings, P., Mills, A.K., Gill, D., Bardy, P., Campbell, L., Seymour, J.F., on behalf of the Australasian Leukaemia & Lymphoma Group
Idarubicin dose escalation during consolidation therapy for adult acute myeloid leukemia
(2017) Journal of Clinical Oncology, 35 (15), pp. 1678-1685.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85022217888&doi=10.1200%2fJCO.2016.70.6374&partnerID=40&md5=2562d1e23225275be1bc6961670774e7

Hopkins, B., Gold, M., **Wei, A**., Grigoriadis, G.
Improving the transition to palliative care for patients with acute leukemia: A coordinated care approach
(2017) Cancer Nursing, 40 (3), pp. E17-E23.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962077686&doi=10.1097%2fNCC.0000000000000368&partnerID=40&md5=f47193e4fc08edf2ad831932eea8231d

Fleming, S., Ong, D.M., Jackson, K., Avery, S., Mollee, P., Marlton, P., Kennedy, G., **Wei, A**.H.
Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia
(2017) British Journal of Haematology, 177 (2), pp. 328-330.

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84963520664&doi=10.1111%2fbjh.14063&partnerID=40&md5=8bc78fa7cccd8a55af842134b38b8a38

Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A.K., Schuh, A.C., Ribera, J.-M., **Wei, A**., Dombret, H., Foà, R., Bassan, R., Arslan, Ö., Sanz, M.A., Bergeron, J., Demirkan, F., Lech-Maranda, E., Rambaldi, A., Thomas, X., Horst, H.-A., Brüggemann, M., Klapper, W., Wood, B.L., Fleishman, A., Nagorsen, D., Holland, C., Zimmerman, Z., Topp, M.S.
Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
(2017) New England Journal of Medicine, 376 (9), pp. 836-847.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014771892&doi=10.1056%2fNEJMoa1609783&partnerID=40&md5=71080c2228e536b3e331d622552e8fcc

Brumatti, G., Lalaoui, N., **Wei, A**.H., Silke, J.
'Did He Who Made the Lamb Make Thee?' New Developments in Treating the 'Fearful Symmetry' of Acute Myeloid Leukemia
(2017) Trends in Molecular Medicine, 23 (3), pp. 264-281.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85012014499&doi=10.1016%2fj.molmed.2017.01.005&partnerID=40&md5=f8187f63d8ee77ab45d0065cfa5c3eed

Powell, J.A., Lewis, A.C., Zhu, W., Toubia, J., Pitman, M.R., Wallington-Beddoe, C.T., Moretti, P.A.B., Iarossi, D., Samaraweera, S.E., Cummings, N., Ramshaw, H.S., Thomas, D., **Wei, A**.H., Lopez, A.F., D'Andrea, R.J., Lewis, I.D., Pitson, S.M.
Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia
(2017) Blood, 129 (6), pp. 771-782.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015282085&doi=10.1182%2fblood-2016-06-720433&partnerID=40&md5=9d8dc9ea29d40bad8c8c600787644a80

Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F.R., Büchner, T., Dombret, H., Ebert, B.L., Fenaux, P., Larson, R.A., Levine, R.L., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M., Sierra, J., Tallman, M.S., Tien, H.-F., **Wei, A**.H., Löwenberg, B., Bloomfield, C.D.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
(2017) Blood, 129 (4), pp. 424-447.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014879329&doi=10.1182%2fblood-2016-08-733196&partnerID=40&md5=1a7a16c2b305e28687e3b30a5faa8089

Swords, R.T., Greenberg, P.L., **Wei, A**.H., Durrant, S., Advani, A.S., Hertzberg, M.S., Lewis, I.D., Rivera, G., Gratzinger, D., Fan, A.C., Felsher, D.W., Cortes, J.E., Watts, J.M., Yarranton, G.T., Walling, J.M., Lancet, J.E.
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
(2016) Leukemia Research, 50, pp. 123-131.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991444268&doi=10.1016%2fj.leukres.2016.09.012&partnerID=40&md5=23b07ad495d7984ee400333511fcaafc

Lalaoui, N., Hänggi, K., Brumatti, G., Chau, D., Nguyen, N.-Y.N., Vasilikos, L., Spilgies, L.M., Heckmann, D.A., Ma, C., Ghisi, M., Salmon, J.M., Matthews, G.M., de Valle, E., Moujalled, D.M., Menon, M.B., Spall, S.K., Glaser, S.P., Richmond, J., Lock, R.B., Condon, S.M.,

Gugasyan, R., Gaestel, M., Guthridge, M., Johnstone, R.W., Munoz, L., **Wei, A**., Ekert, P.G., Vaux, D.L., Wong, W.W.-L., Silke, J.
Correction: Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics (Cancer Cell (2016) 30(3) (499–500) (S1535610816000350) (10.1016/j.ccell.2016.01.006))
(2016) Cancer Cell, 30 (3), pp. 499-500.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84995610411&doi=10.1016%2fj.ccell.2016.08.009&partnerID=40&md5=c71caf114469939e9c609212317cfde3

Guirguis, A.A., Slape, C.I., Failla, L.M., Saw, J., Tremblay, C.S., Powell, D.R., Rossello, F., **Wei, A**., Strasser, A., Curtis, D.J.
PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia
(2016) Cell Death and Differentiation, 23 (6), pp. 1049-1059.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84953455395&doi=10.1038%2fcdd.2015.159&partnerID=40&md5=fc2c41f84e6d56b831ca6da77407c309

Brumatti, G., Ma, C., Lalaoui, N., Nguyen, N.-Y., Navarro, M., Tanzer, M.C., Richmond, J., Ghisi, M., Salmon, J.M., Silke, N., Pomilio, G., Glaser, S.P., De Valle, E., Gugasyan, R., Gurthridge, M.A., Condon, S.M., Johnstone, R.W., Lock, R., Salvesen, G., **Wei, A**., Vaux, D.L., Ekert, P.G., Silke, J.
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia
(2016) Science Translational Medicine, 8 (339), art. no. 339ra69, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969595271&doi=10.1126%2fscitranslmed.aad3099&partnerID=40&md5=7879f58d65c8e7a9a195b43ec774c34f

Graves, B., Morrissey, C.O., **Wei, A**., Coutsouvelis, J., Ellis, S., Pham, A., Gooi, J., Ananda-Rajah, M.
Isavuconazole as salvage therapy for mucormycosis
(2016) Medical Mycology Case Reports, 11, pp. 36-39.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964267886&doi=10.1016%2fj.mmcr.2016.03.002&partnerID=40&md5=037a80fed4ad0d46336e0fefc4cd5a73

Lalaoui, N., Hänggi, K., Brumatti, G., Chau, D., Nguyen, N.-Y.N., Vasilikos, L., Spilgies, L.M., Heckmann, D.A., Ma, C., Ghisi, M., Salmon, J.M., Matthews, G.M., de Valle, E., Moujalled, D.M., Menon, M.B., Spall, S.K., Glaser, S.P., Richmond, J., Lock, R.B., Condon, S.M., Gugasyan, R., Gaestel, M., Guthridge, M., Johnstone, R.W., Munoz, L., **Wei, A**., Ekert, P.G., Vaux, D.L., Wong, W.W.L., Silke, J.
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics
(2016) Cancer Cell, 29 (2), pp. 145-158.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958646766&doi=10.1016%2fj.ccell.2016.01.006&partnerID=40&md5=6da490d40236f6324ee4e3e30170bab7

Roboz, G.J., Montesinos, P., Selleslag, D., **Wei, A**., Jang, J.-H., Falantes, J., Voso, M.T., Sayar, H., Porkka, K., Marlton, P., Almeida, A., Mohan, S., Ravandi, F., Garcia-Manero, G., Skikne, B., Kantarjian, H.
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

(2016) Future Oncology, 12 (3), pp. 293-302.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961348336&doi=10.2217%2ffon.15.326&partnerID=40&md5=4dc3a0eb5476bd83a4b6bb1e96cea7d3

Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A.L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G.L., Gong, J.-N., Moujalled, D.M., Bruno, A., Csekei, M., Paczal, A., Szabo, Z.B., Sipos, S., Radics, G., Proszenyak, A., Balint, B., Ondi, L., Blasko, G., Robertson, A., Surgenor, A., Dokurno, P., Chen, I., Matassova, N., Smith, J., Pedder, C., Graham, C., Studeny, A., Lysiak-Auvity, G., Girard, A.-M., Gravé, F., Segal, D., Riffkin, C.D., Pomilio, G., Galbraith, L.C.A., Aubrey, B.J., Brennan, M.S., Herold, M.J., Chang, C., Guasconi, G., Cauquil, N., Melchiore, F., Guigal-Stephan, N., Lockhart, B., Colland, F., Hickman, J.A., Roberts, A.W., Huang, D.C.S., **Wei, A**.H., Strasser, A., Lessene, G., Geneste, O.
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
(2016) Nature, 538 (7626), pp. 477-482.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84993984528&doi=10.1038%2fnature19830&partnerID=40&md5=e13740552c0b445d9734dea0bab05917

Saulep-Easton, D., Vincent, F.B., Quah, P.S., **Wei, A**., Ting, S.B., Croce, C.M., Tam, C., MacKay, F.
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells
(2016) Leukemia, 30 (1), pp. 163-172.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84953354183&doi=10.1038%2fleu.2015.174&partnerID=40&md5=610c1faf44d818106eafc4bbc1b21220

Bryant, J., Sanson-Fisher, R., Stevenson, W., Smits, R., Henskens, F., **Wei, A**., Tzelepis, F., D'Este, C., Paul, C., Carey, M.
Protocol of a multi-centre randomised controlled trial of a web-based information intervention with nurse-delivered telephone support for haematological cancer patients and their support persons
(2015) BMC Cancer, 15 (1), art. no. 295, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928560014&doi=10.1186%2fs12885-015-1314-x&partnerID=40&md5=2bef1a4fe2319b81ac4c20a420d4bb3f

Ling, V.Y., Lee, D., Mcquilten, Z., Avery, S., Low, M., Cody, S.H., Nguyen, T., Mclean, C., Gorniak, M., **Wei, A**., Ting, S.B.
Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia
(2015) American Journal of Hematology, 90 (12), pp. E219-E220.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84954380459&doi=10.1002%2fajh.24179&partnerID=40&md5=f442934314440cdc8bf646dd63fbeba2

Pham, T., Patil, S., Fleming, S., Avery, S., Walker, P., **Wei, A**., Curtis, D., Stuart, G., Klarica, D., O'Brien, M., Morris, K., Das, T., Bollard, G., Muirhead, J., Coutsouvelis, J., Spencer, A.
Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation
(2015) Transfusion, 55 (11), pp. 2709-2713.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84947077026&doi=10.1111%2ftrf.13233&partnerID=40&md5=e908060393c167ffc7c384acbfc91fcc

Phillipson, L.J., Segal, D.H., Nero, T.L., Parker, M.W., Wan, S.S., De Silva, M., Guthridge, M.A., **Wei, A**.H., Burns, C.J.
Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9
(2015) Bioorganic and Medicinal Chemistry, 23 (19), art. no. 12539, pp. 6280-6296.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941944212&doi=10.1016%2fj.bmc.2015.08.035&partnerID=40&md5=d2522ed2416d125e360cf9bd43700481

Ravandi, F., Ritchie, E.K., Sayar, H., Lancet, J.E., Craig, M.D., Vey, N., Strickland, S.A., Schiller, G.J., Jabbour, E., Erba, H.P., Pigneux, A., Horst, H.-A., Recher, C., Klimek, V.M., Cortes, J., Roboz, G.J., Odenike, O., Thomas, X., Havelange, V., Maertens, J., Derigs, H.-G., Heuser, M., Damon, L., Powell, B.L., Gaidano, G., Carella, A.-M., **Wei, A**., Hogge, D., Craig, A.R., Fox, J.A., Ward, R., Smith, J.A., Acton, G., Mehta, C., Stuart, R.K., Kantarjian, H.M.
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study
(2015) The Lancet Oncology, 16 (9), art. no. 169, pp. 1025-1036.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84940612285&doi=10.1016%2fS1470-2045%2815%2900201-6&partnerID=40&md5=abe14983311e7ae5c018971a590c55e6

Lee, E.M., Yee, D., Busfield, S.J., McManus, J.F., Cummings, N., Vairo, G., We, A., Ramshaw, H.S., Powell, J.A., Lopez, A.F., Lewis, I.D., McCall, M.N., Lock, R.B.
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
(2015) Haematologica, 100 (7), pp. 914-926.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84936155053&doi=10.3324%2fhaematol.2014.113092&partnerID=40&md5=a043d8e7705b27699687de79ef66170f

Wei, A., Tan, P., Perruzza, S., Govindaraj, C., Fleming, S., Mcmanus, J., Avery, S., Patil, S., Stevenson, W., Plebanski, M., Spencer, A.
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia
(2015) British Journal of Haematology, 169 (2), pp. 199-210.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926310726&doi=10.1111%2fbjh.13281&partnerID=40&md5=c85949670daf600456117a35b0b7cc60

Rijal, S., Fleming, S., Cummings, N., Rynkiewicz, N.K., Ooms, L.M., Nguyen, N.-Y.N., Teh, T.-C., Avery, S., McManus, J.F., Papenfuss, A.T., McLean, C., Guthridge, M.A., Mitchell, C.A., **Wei, A**.H.
Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML
(2015) Blood, 125 (18), pp. 2815-2824.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928787729&doi=10.1182%2fblood-2014-09-603555&partnerID=40&md5=bd4e9f1c71cb31e8921408d33d1ab18e

Wei, A.
ABT-199 partners with azacitidine to contest myeloid malignancies
(2015) Leukemia and Lymphoma, 56 (1), pp. 8-9.

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84922362156&doi=10.3109%2f10428194.2014.919638&partnerID=40&md5=666a9992815340bdf05b782483eef408

Saulep-Easton, D., Vincent, F.B., Le Page, M., **Wei, A**., Ting, S.B., Croce, C.M., Tam, C., Mackay, F.
Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia
(2014) Leukemia, 28 (10), pp. 2005-2015.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84916231643&doi=10.1038%2fleu.2014.105&partnerID=40&md5=b1abdb662a4b73de044d075a3073d25b

Cummins, K.D., Jane, S.M., Nikovic, S., Bazargan, A., Filshie, R., Sutrave, G., Hertzberg, M., Scott, A., Lane, S., Yannakou, C.K., Ritchie, D., D'Rozario, J., Black, J., Bavishi, K., **Wei, A**.
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
(2014) Blood Cancer Journal, 4 (8), art. no. e237, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906854162&doi=10.1038%2fbcj.2014.59&partnerID=40&md5=a9735a203b29bd74d381b3d2c36fed3b

Iland, H.J., Seymour, J.F., **Wei, A**.
Optimal approach for high-risk acute promyelocytic leukemia
(2014) Current Opinion in Hematology, 21 (2), pp. 102-113.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894067674&doi=10.1097%2fMOH.0000000000000025&partnerID=40&md5=182a45853b52ae346c1cb6ae6cf2addf

Govindaraj, C., Tan, P., Walker, P., **Wei, A**., Spencer, A., Plebanski, M.
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in Acute myeloid leukemia patients
(2014) Clinical Cancer Research, 20 (3), pp. 724-735.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893511220&doi=10.1158%2f1078-0432.CCR-13-1576&partnerID=40&md5=e1cdc41ebbc67eb2b7fe5dbc5f1e88bb

Cummins, K.D., Jane, S.M., Ninkovic, S., Bazargan, A., Filshie, R., Sutrave, G., Hertzberg, M., Scott, A., Lane, S., Yannakou, C.K., Ritchie, D., D'Rozario, J., Black, J., Bavishi, K., **Wei, A**.
Erratum: Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia (Blood Cancer Journal (2014) 4 (e237) DOI: 10.1038/bcj.2014.59)
(2014) Blood Cancer Journal, 4 (9), art. no. e246, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84927745055&doi=10.1038%2fbcj.2014.68&partnerID=40&md5=8df1456fdc7617f553db23d438c9127b

Wei, A., Fleming, S.
Author reply
(2014) Internal Medicine Journal, 44 (8), pp. 825-825.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905185087&doi=10.1111%2fimj.12506&partnerID=40&md5=7253866d05403155c314baa38bc2bf4f

Fedele, P.L., Avery, S., Patil, S., Spencer, A., Haas, M., **Wei, A**.

Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia
(2014) Internal Medicine Journal, 44 (8), pp. 757-763.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905157915&doi=10.1111%2fimj.12478&partnerID=40&md5=0feb9355e391c496b79f8ce3229d16b1

Govindaraj, C., Madondo, M., Kong, Y.Y., Tan, P., **Wei, A**., Plebanski, M.
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients
(2014) American Journal of Hematology, 89 (8), pp. 795-802.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904386072&doi=10.1002%2fajh.23746&partnerID=40&md5=19c8de231f0e01890e2d674d8f5a40d1

Iland, H.J., **Wei, A**., Seymour, J.F.
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care
(2014) Best Practice and Research: Clinical Haematology, 27 (1), pp. 39-52.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902192960&doi=10.1016%2fj.beha.2014.04.003&partnerID=40&md5=dc4a34e30db2a7dd5885931ea5f11b1f

Campbell, P., Walker, P., Avery, S., Patil, S., Curtis, D., Schwarer, A., **Wei, A**., Kalff, A., Muirhead, J., Spencer, A.
Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
(2014) Blood Cancer Journal, 4 (5), art. no. 213, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902006998&doi=10.1038%2fbcj.2014.33&partnerID=40&md5=e5103aa721d3f4e833824a011185cf9b

Tan, P., **Wei, A**., Mithraprabhu, S., Cummings, N., Liu, H.B., Perugini, M., Reed, K., Avery, S., Patil, S., Walker, P., Mollee, P., Grigg, A., D'Andrea, R., Dear, A., Spencer, A.
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
(2014) Blood Cancer Journal, 4 (1), art. no. e170, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892413294&doi=10.1038%2fbcj.2013.68&partnerID=40&md5=dcea05bb823b8f3528a4be9a3a87c8b2

Chieng, R., Coutsouvelis, J., Poole, S., Dooley, M.J., Booth, D., **Wei, A**.
Improving the transition of highly complex patients into the community: Impact of a pharmacist in an allogeneic stem cell transplant (SCT) outpatient clinic
(2013) Supportive Care in Cancer, 21 (12), pp. 3491-3495.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84889080183&doi=10.1007%2fs00520-013-1938-9&partnerID=40&md5=5cb5c378bbaec1e201e9da3e0026ba61

Jaworski, C., Looi, J.-L., Martin, J., Bergin, P., Hare, J., Kaye, D., **Wei, A**., Taylor, A.J.
Cardiac imaging in FIP1L1-PDGFRA
(2013) Journal of the American College of Cardiology, 62 (14), p. 1304.

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84884569693&doi=10.1016%2fj.jacc.2013.04.099&partnerID=40&md5=97528255a8996165d0a5f00938fb1e2c

Thomas, D., Powell, J.A., Vergez, F., Segal, D.H., Nguyen, N.-Y.N., Baker, A., Teh, T.-C., Barry, E.F., Sarry, J.-E., Lee, E.M., Nero, T.L., Jabbour, A.M., Pomilio, G., Green, B.D., Manenti, S., Glaser, S.P., Parker, M.W., Lopez, A.F., Ekert, P.G., Lock, R.B., Huang, D.C.S., Nilsson, S.K., Récher, C., **Wei, A**.H., Guthridge, M.A.
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription
(2013) Blood, 122 (5), pp. 738-748.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886439344&doi=10.1182%2fblood-2012-08-447441&partnerID=40&md5=5a51c4a93ef432bc4056a4d53f7b0f3f

Kantarjian, H.M., Martinelli, G., Jabbour, E.J., Quintás-Cardama, A., Ando, K., Bay, J.-O., **Wei, A**., Gröpper, S., Papayannidis, C., Owen, K., Pike, L., Schmitt, N., Stockman, P.K., Giagounidis, A.
Stage i of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
(2013) Cancer, 119 (14), pp. 2611-2619.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879644165&doi=10.1002%2fcncr.28113&partnerID=40&md5=e6774e32b3f1281b00bce445683650f6

Sleebs, B.E., Kersten, W.J.A., Kulasegaram, S., Nikolakopoulos, G., Hatzis, E., Moss, R.M., Parisot, J.P., Yang, H., Czabotar, P.E., Fairlie, W.D., Lee, E.F., Adams, J.M., Chen, L., Van Delft, M.F., Lowes, K.N., **Wei, A**., Huang, D.C.S., Colman, P.M., Street, I.P., Baell, J.B., Watson, K., Lessene, G.
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL
(2013) Journal of Medicinal Chemistry, 56 (13), pp. 5514-5540.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880180686&doi=10.1021%2fjm400556w&partnerID=40&md5=6e1635fd687a99930139a9deb45b80cc

Perugini, M., Iarossi, D.G., Kok, C.H., Cummings, N., Diakiw, S.M., Brown, A.L., Danner, S., Bardy, P., Bik To, L., **Wei, A**.H., Lewis, I.D., D'Andrea, R.J.
GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations
(2013) Leukemia, 27 (7), pp. 1588-1592.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880312982&doi=10.1038%2fleu.2012.346&partnerID=40&md5=e1472c70a439acef8d834a072777315a

Diakiw, S.M., Perugini, M., Kok, C.H., Engler, G.A., Cummings, N., To, L.B., **Wei, A**.H., Lewis, I.D., Brown, A.L., D'Andrea, R.J.
Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival
(2013) British Journal of Haematology, 161 (6), pp. 884-888.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878485138&doi=10.1111%2fbjh.12295&partnerID=40&md5=7efa0aea545d5f7f5118148686cc5641

Smeets, M.F.M.A., Chan, A.C., Dagger, S., Bradley, C.K., **Wei, A**., Izon, D.J.

Fli-1 Overexpression in Hematopoietic Progenitors Deregulates T Cell Development and Induces Pre-T Cell Lymphoblastic Leukaemia/Lymphoma
(2013) PLoS ONE, 8 (5), art. no. e62346, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84877137854&doi=10.1371%2fjournal.pone.0062346&partnerID=40&md5=7cb6ae425820607e06614dd959997b71

Wei, A., Tan, P.
Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia
(2013) Leukemia and Lymphoma, 54 (4), pp. 675-676.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879508921&doi=10.3109%2f10428194.2012.731604&partnerID=40&md5=dac44c51cccfa15af245454f735e0876

Thomas, D., Powell, J.A., Green, B.D., Barry, E.F., Ma, Y., Woodcock, J., Fitter, S., Zannettino, A.C.W., Pitson, S.M., Hughes, T.P., Lopez, A.F., Shepherd, P.R., **Wei, A**.H., Ekert, P.G., Guthridge, M.A.
Protein Kinase Activity of Phosphoinositide 3-Kinase Regulates Cytokine-Dependent Cell Survival
(2013) PLoS Biology, 11 (3), art. no. e1001515, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84875456580&doi=10.1371%2fjournal.pbio.1001515&partnerID=40&md5=246c7238c0b093567e0dc60ac6813528

Low, M., Lee, D., Coutsouvelis, J., Patil, S., Opat, S., Walker, P., Schwarer, A., Salem, H., Avery, S., Spencer, A., **Wei, A**.
High-dose cytarabine (24g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia
(2013) Internal Medicine Journal, 43 (3), pp. 294-297.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874379976&doi=10.1111%2fj.1445-5994.2012.02868.x&partnerID=40&md5=c7ed3fc84b9c2693197299007753dbda

Fong, C.Y., Grigoriadis, G., Hocking, J., Coutsouvelis, J., Muirhead, J., Campbell, P., Paul, E., Walker, P., Avery, S., Patil, S., Spencer, A., Schwarer, A., **Wei, A**.
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: An effective salvage therapy option for acute myeloid leukemia at first relapse
(2013) Leukemia and Lymphoma, 54 (2), pp. 336-341.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872048218&doi=10.3109%2f10428194.2012.713479&partnerID=40&md5=29adbab54ccac35e6246ff2f9686ee3f

Ling, V., Burnett, A.K., Bradstock, K., Seymour, J.F., Hills, R.K., **Wei, A**.
Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy
(2013) British Journal of Haematology, 160 (6), pp. 861-863.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874729279&doi=10.1111%2fbjh.12178&partnerID=40&md5=2a94e8c737d65921cafe521204b3f30a

Coutsouvelis, J., Wiseman, M., Hui, L., Poole, S., Dooley, M., Patil, S., Avery, S., **Wei, A**., Spencer, A.

Effectiveness of a single fixed dose of rasburicase 3mg in the management of tumour lysis syndrome
(2013) British Journal of Clinical Pharmacology, 75 (2), pp. 565-568.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872236403&doi=10.1111%2fj.1365-2125.2012.04355.x&partnerID=40&md5=3ee1d36721e9f9d1e0e942c82481d542

Tan, A.Y.-C., Wong, S.Q., Nyvold, C.G., Carney, D.A., **Wei, A**., Seymour, J.F., Hokland, P., Westerman, Dobrovic, A.
Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis
(2012) Leukemia and Lymphoma, 53 (6), pp. 1225-1229.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84861364396&doi=10.3109%2f10428194.2011.645817&partnerID=40&md5=5b989f21eae26c7b7de2664a2a9af9a8

Glaser, S.P., Lee, E.F., Trounson, E., Bouillet, P., **Wei, A**., Fairlie, W.D., Izon, D.J., Zuber, J., Rappaport, A.R., Herold, M.J., Alexander, W.S., Lowe, S.W., Robb, L., Strasser, A.
Anti-apoptotic mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
(2012) Genes and Development, 26 (2), pp. 120-125.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856270102&doi=10.1101%2fgad.182980.111&partnerID=40&md5=c4c5228512a89bad1ea0179c485e401f

Van Der Jagt, A., Muirhead, J., Seymour, J.F., Bradstock, K.F., Paul, E., **Wei, A**.
Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML
(2012) Leukemia, 26 (2), pp. 362-365.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856751417&doi=10.1038%2fleu.2011.201&partnerID=40&md5=fc5227ca5178e3918f5df5abb2390764

Wei, A., Teh, T.-C.
Salvaging AML with CLAG: Novel option, or more of the same?
(2011) Leukemia Research, 35 (3), pp. 297-298.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952104397&doi=10.1016%2fj.leukres.2010.10.015&partnerID=40&md5=de1a1e39c628c2bbe695b43ee5d70e22

Tan, P.T., **Wei, A**.H.
The epigenomics revolution in myelodysplasia: A clinico-pathological perspective
(2011) Pathology, 43 (6), pp. 536-546.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-81555216957&doi=10.1097%2fPAT.0b013e32834a4061&partnerID=40&md5=fd5e45e0320aaebbbc3c9842245352b8

Slavin, M.A., Lingaratnam, S., Mileshkin, L., Booth, D.L., Cain, M.J., Ritchie, D.S., **Wei, A**., Thursky, K.A.
Use of antibacterial prophylaxis for patients with neutropenia
(2011) Internal Medicine Journal, 41 (1 B), pp. 102-109.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-79251554095&doi=10.1111%2fj.1445-5994.2010.02341.x&partnerID=40&md5=908de6d448e4387d3f9158984d86c21b

Worth, L.J., Lingaratnam, S., Taylor, A., Hayward, A.M., Morrissey, S., Cooney, J., Bastick, P.A., Eek, R.W., **Wei, A**., Thursky, K.A.
Use of risk stratification to guide ambulatory management of neutropenic fever
(2011) Internal Medicine Journal, 41 (1 B), pp. 82-89.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-79251535927&doi=10.1111%2fj.1445-5994.2010.02339.x&partnerID=40&md5=c4cc3891cedeb992fcd7ed12a7790c9b

Kvansakul, M., **Wei, A**.H., Fletcher, J.I., Willis, S.N., Chen, L., Roberts, A.W., Huang, D.C.S., Colman, P.M.
Structural basis for apoptosis inhibition by Epstein-Barr virus bhrf1
(2010) PLoS Pathogens, 6 (12), art. no. e1001236, .
https://www.scopus.com/inward/record.uri?eid=2-s2.0-78651262604&doi=10.1371%2fjournal.ppat.1001236&partnerID=40&md5=211c12f5087b370302fc9729ae8f35b7

Patil, S., Spencer, A., Schwarer, A., Lewis, I., Hertzberg, M., Avery, S., **Wei, A**., Noutsos, T., Paul, E., Taouk, Y., Muirhead, J.
Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: Eighty-month follow-up
(2010) Bone Marrow Transplantation, 45 (7), pp. 1154-1160.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955012530&doi=10.1038%2fbmt.2009.322&partnerID=40&md5=428baff1fde68a3f3a641278efc47a20

Minden, M., **Wei, A**.
Revisiting late relapses in acute myeloid leukemia
(2010) Leukemia and Lymphoma, 51 (5), pp. 735-736.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951875869&doi=10.3109%2f10428194.2010.483750&partnerID=40&md5=5f8dbc4fc763a97152a42532faa18aed

Douglass, J.A., Carroll, K., Voskamp, A., Bourke, P., **Wei, A**., O'Hehir, R.E.
Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient
(2010) Allergy: European Journal of Allergy and Clinical Immunology, 65 (7), pp. 926-927.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953105527&doi=10.1111%2fj.1398-9995.2009.02259.x&partnerID=40&md5=9ace78cfff6d580424ef5a5347580223

Patil, S., Spencer, A., Schwarer, A., Avery, S., Ritchie, D., Opat, S., **Wei, A**., McLean, C.
Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with Neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
(2009) Leukemia and Lymphoma, 50 (12), pp. 1964-1968.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-72949112708&doi=10.3109%2f10428190903288456&partnerID=40&md5=d3f80e0e939fc9eaf46a49a811e8dd5d

Wei, A.H., Schoenwaelder, S.M., Andrews, R.K., Jackson, S.P.
New insights into the haemostatic function of platelets
(2009) British Journal of Haematology, 147 (4), pp. 415-430.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350435452&doi=10.1111%2fj.1365-2141.2009.07819.x&partnerID=40&md5=d7c9887d90e063f50a20c175a750bdce

Mason, K.D., Vandenberg, C.J., Scott, C.L., **Wei, A**.H., Cory, S., Huang, D.C.S., Roberts, A.W.
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
(2008) Proceedings of the National Academy of Sciences of the United States of America, 105 (46), pp. 17961-17966.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-56649120608&doi=10.1073%2fpnas.0809957105&partnerID=40&md5=0e49c1784594f73a33d505785f46b78d

Ng, S.K., Epari, K., Parsons, S., **Wei, A**., Banting, S.W.
Extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue of the gallbladder
(2008) Surgical Practice, 12 (4), pp. 137-141.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-54049085383&doi=10.1111%2fj.1744-1633.2008.00418.x&partnerID=40&md5=fe44682663553b0b7732e769c314bb6a

Wei, A., Jackson, S.P.
Boosting platelet production
(2008) Nature Medicine, 14 (9), pp. 917-918.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-51349128259&doi=10.1038%2fnm0908-917&partnerID=40&md5=c8fe8a86e1f49f8dfc3a6c65052f4232

Wei, A.H., Roberts, A.W.
Bortezomib: Putting mantle cell lymphoma on death row
(2008) Leukemia and Lymphoma, 49 (4), pp. 657-658.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-42049112840&doi=10.1080%2f10428190801942378&partnerID=40&md5=151248258ac0c99b62a4324cac614345

Wei, A., Alison, J., Goldstein, J., Tippett, C., Coughlan, P.B.
Prosthetic pulmonary valve thrombosis in pregnancy successfully treated with thrombolysis
(2008) Internal Medicine Journal, 38 (2), pp. 142-143.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-39149131391&doi=10.1111%2fj.1445-5994.2007.01559.x&partnerID=40&md5=67bf6ef33d1be8456ae8a5cdd809f3da

Wei, A., Cowie, T.
Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene
(2007) European Journal of Haematology, 79 (4), pp. 363-366.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548590302&doi=10.1111%2fj.1600-0609.2007.00924.x&partnerID=40&md5=f71809a84763a50be82146be142f4cea

Lindemann, R.K., Newbold, A., Whitecross, K.F., Cluse, L.A., Frew, A.J., Ellis, L., Williams, S., Wiegmans, A.P., Dear, A.E., Scott, C.L., Pellegrini, M., **Wei, A**., Richon, V.M., Marks, P.A., Lowe, S.W., Smyth, M.J., Johnstone, R.W.
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
(2007) Proceedings of the National Academy of Sciences of the United States of America, 104 (19), pp. 8071-8076.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-34249941680&doi=10.1073%2fpnas.0702294104&partnerID=40&md5=a01d1b223439c5fe445f4c990b2d5dbf

Chew, E., Filshie, R., **Wei, A**.
Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone [12]
(2007) Leukemia and Lymphoma, 48 (1), pp. 212-213.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247207092&doi=10.1080%2f10428190600988010&partnerID=40&md5=554ee4affd62fea013079530a79ac575

Ng, A.P., **Wei, A**., Bhurani, D., Chapple, P., Feleppa, F., Juneja, S.
The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells
(2006) Haematologica, 91 (7), pp. 972-975.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745780477&partnerID=40&md5=87a45ccdcb2b2a1a0c6c0c9721a270d7

van Delft, M.F., **Wei, A**.H., Mason, K.D., Vandenberg, C.J., Chen, L., Czabotar, P.E., Willis, S.N., Scott, C.L., Day, C.L., Cory, S., Adams, J.M., Roberts, A.W., Huang, D.C.S.
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
(2006) Cancer Cell, 10 (5), pp. 389-399.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750834023&doi=10.1016%2fj.ccr.2006.08.027&partnerID=40&md5=0f12523b5669c91cfe8ea15afa3394cb

Adams, J.M., Huang, D.C.S., Strasser, A., Willis, S., Chen, L., **Wei, A**., Van Delft, M., Fletcher, J.I., Puthalakath, H., Kuroda, J., Michalak, E.M., Kelly, P.N., Bouillet, P., Villunger, A., O'Reilly, L., Bath, M.L., Smith, D.P., Egle, A., Harris, A.W., Hinds, M., Colman, P., Cory, S.
Subversion of the Bcl-2 life/death switch in cancer development and therapy
(2005) Cold Spring Harbor Symposia on Quantitative Biology, 70, pp. 469-477.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-33746388295&doi=10.1101%2fsqb.2005.70.009&partnerID=40&md5=97c2685af5d5f67e945a42acc121044a

Wei, A., Westerman, D., Feleppa, F., Trivett, M., Juneja, S.
Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma
(2005) Haematologica, 90 (8), pp. 1147-1149.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-24944437121&partnerID=40&md5=f48db9ab9f2960de634574b027f2cb85

Willis, S.N., Chen, L., Dewson, G., **Wei, A**., Naik, E., Fletcher, J.I., Adams, J.M., Huang, D.C.S.
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
(2005) Genes and Development, 19 (11), pp. 1294-1305.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-22244464818&doi=10.1101%2fgad.1304105&partnerID=40&md5=db3c6e304cf4f6c259f66192d81c3860

Chen, L., Willis, S.N., **Wei, A**., Smith, B.J., Fletcher, J.I., Hinds, M.G., Colman, P.M., Day, C.L., Adams, J.M., Huang, D.C.S.
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

(2005) Molecular Cell, 17 (3), pp. 393-403.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-19944432123&doi=10.1016%2fj.molcel.2004.12.030&partnerID=40&md5=fe127524e6da8b36098f668fe152f6c1

Wei, A., Juneja, S.
Bone marrow immunohistology of plasma cell neoplasms
(2003) Journal of Clinical Pathology, 56 (6), pp. 406-411.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037972378&doi=10.1136%2fjcp.56.6.406&partnerID=40&md5=6405a33c4681ea06f9be3fb052305150

Wei, A., Grigg, A.
Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/β+ thalassemia [1]
(2001) Blood, 97 (12), pp. 3998-3999.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035878007&doi=10.1182%2fblood.V97.12.3998&partnerID=40&md5=a12a990325bbd9ee1a3997a013fa906b

Wei, A.H., Juneja, S.K., Szer, J.
Acute myeloid leukemia (FAB-M4) with eosinophilia in a patient with metastatic breast cancer
(2001) Haematologica, 86 (4), p. 446.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035023253&partnerID=40&md5=4bdffa3531d2af3a95f384a00c94dcca

M. PATENTS

Filing Date: 21/07/2017. Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof. A. Wei, D. Moujalled, G. Pomilio, A.L. Maragno, O. Geneste, A. Claperon, H. Maacke, E. Halilovic, D. Porter, E. Morris, Y. Wang, S. Sanghavi and P. Mistry. International Application No.: PCT/EP2017/068453

Filing date: 22/7/2016. Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof. A. Wei, D. Moujalled and G. Pomilio. EP patent 16180918.1-1466

Filing date: 28/10/2016. Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof. A. Wei, D. Moujalled, G. Pomilio, A.L. Margano, O. Geneste and A. Claperon. EP patent 16306420.7-1466
2012 Bak as a biomarker for targeted cancer therapies. A. Wei and M. Guthridge Australian Provisional Patent Application No. 2011905134

2005 Therapeutic molecules and methods for generating and/or selecting same. D. Huang, P.M. Colman, C.L. Day, J.M. Adams, L. Chen, S.N. Willis, A. Wei, B.J. Smith, MG EP Patent 1,718,748, US Patent App. 20,080/027,145
2005 Conjugates And Therapeutic Uses Thereof. J. Baell, A.H. Wei and D.B. Scanlon. US Patent App. 20,070/197,430, US Patent App. 11/571,160

N. CLINICAL TRIAL ACTIVITIES

Investigator initiated studies as principal researcher

1. Phase 1 study of RAD001 and low dose ara-C for elderly AML
2. Phase 1 study of azacitidine and lenalidomide as maintenance therapy in AML
3. Phase 1 study of azacitidine and everolimus in relapsed AML
4. Phase 1 multicentre ALLG study of lenalidomide maintenance therapy in AML
5. Phase 2 randomised controlled multicentre ALLG study of Sorafenib in FLT3-ITD AML
6. Phase 2 randomised multicentre ALLG study of high-dose lenalidomide and azacitidine and depsipeptide in relapsed AML
7. Phase 2 randomised multicentre ALLG study of ponatinib and azacitidine in relapsed/refractory FLT3-ITD AML
8. Phase 1b Chemotherapy and Venetoclax in Elderly AML (CAVEAT)

Co-operative group studies local site principal investigator

1. Phase 3 study: ALLG AML M12 study
2. Phase 2 study: ALLG APML M4 study
3. Phase 2/3: UK MRC16 AML study
4. Phase 2/3: UK MRC LI-1 AML study

Commercially sponsored studies as local site principal investigator

1. Phase 2 study: CEP-701 in relapsed AML
2. Phase 2 study: AS1411 in relapsed AML
3. Phase 2 study: Midostaurin in systemic mastocytosis
4. Phase 2/3 study: AZD1152 in older AML
5. Phase 3: PKC412 in AML
6. Phase 3: Amonafide in secondary AML
7. Phase 3: Elacytarabine in relapsed AML
8. Phase 3: Voreloxin in relapsed AML
9. Phase 1: KB004 in advanced haematological malignancies
10. Phase 1: Meisoindigo in AML unfit for chemotherapy
11. Phase 3: Azacitidine maintenance therapy for AML in CR1
12. Phase 3: Blinatumomab in ALL
13. Phase 1: LDE225 in AML
14. Phase 1: LGH447 in AML
15. Phase 3: AC220 in FLT3-ITD AML
16. Phase 1: LSD1 inhibition in AML
17. Phase 1: S55746 relapsed/refractory high risk MDS and AML
18. Phase 1: ABT-199 + low-dose cytarabine in AML
19. Phase 1: ABT-199 + decitabine in AML
20. Phase 1: IDH305 in IDH1 mutant AML
21. Phase 2/3: MDM2 inhibitor in relapsed/refractory AML
22. Phase 3: AG-221 vs SOC in relapsed/refractory AML
23. Phase 1: AG-120 and AG-221 in combination with azacitidine in elderly AML
24. Phase 1: CD3 x CD123 duobody for advanced AML
25. Phase 1: IDH305 combined with standard therapy as initial therapy in IDH1 mutant AML
26. Phase 2: Decitabine +/- CD123 Ab in elderly unfit AML
27. Phase 2: Azacitidine +/- venetoclax in high risk MDS

28. Phase 2: Decitabine + PD1/TIM3 inhibitors
29. Phase 1: S64315 relapsed/refractory high risk MDS and AML
30. Phase 2: CD123 Ab + decitabine for elderly AML
31. Phase 3: Azacitidine + venetoclax/placebo for elderly unfit AML
32. Phase 3: Low-dose cytarabine + venetoclax/placebo for elderly unfit AML

O. Higher degree student completions
PhD 2015: Sewa Rijal- primary supervisor
MD 2016: Peter Tan- primary supervisor
PhD 2016: Tse-Chieh Teh- primary supervisor
PhD 2015: Chindu Govindaraj- co-supervisor
PhD 2015: Andrew Gruguis- co-supervisor

Ongoing
Shaun Fleming- PhD
Ing-Soo Tiong- MD
Ming-Ong Doen- PhD
Chyn Chua - PhD

Mentoring of post-doctoral fellows
Donia Moujalled- VCA mid career fellowship (2020-2022)
Fiona Brown- NHMRC investigator fellowship (2020-2024)